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1Summary
Brachytherapy is a form of radiotherapy in which radioactive sources are placed at 
short distances from, or even inside the target volume.   The use of high dose rate 
brachytherapy is a widely accepted and clinically proven treatment for some stages of 
prostate cancer.  
The aim of this project was to investigate potential improvements on two of the most 
important aspects of high dose rate (HDR) and pulsed dose rate (PDR) prostate 
brachytherapy – prostate definition and treatment delivery verification.  
The use of magnetic resonance (MR) imaging in addition to the conventional 
computed tomography (CT) imaging methods currently used routinely for 
brachytherapy planning may provide some benefit in accurately defining the prostate 
and surrounding critical structures.  The methods used in this project involved
analysis of data sets provided by two Radiation Oncologists at St George Hospital.  
With only two Oncologists providing the data, the results presented were assessed for 
trends and were not expected to provide statistically rigorous conclusions.  The study 
presented here would require a larger cohort of participating Oncologists to be able to 
draw such conclusions.
The results presented showed inter-observer and intra-observer variations in the size 
and shape of the prostate, as well as analysis of the dosimetric differences that may be 
reported due to the differences in prostate size and shape.  The results also included 
analysis of critical structure dosimetry – dose to the surrounding radio-sensitive 
rectum and urethra.  
In summary, the results showed that the prostate was defined to be smaller using MR 
imaging than CT, however the consistency between Oncologists was not significantly 
improved using MR imaging.  Assuming MR imaging is more accurate than CT in 
defining the prostate as reported in publications such as Menard, Susil et al. (2004), it 
may be useful in reducing the dose to normal tissue surrounding the prostate and in
obtaining better coverage of the smaller target volume, without compromising the 
critical structures.
2The use of LiF:Mg,Ti thermoluminescent dosimeters (TLDs) is a potential avenue for 
in vivo dose verification of an HDR or PDR prostate brachytherapy treatment plan.  
This project included a phantom study of these TLDs with the aim to determine their 
feasibility for clinical use.   Cylindrical TLD rods (6 mm length x 1 mm diameter) 
were used, as these fit inside the brachytherapy needles implanted into the prostate, 
and therefore had potential to be used clinically to verify the dose delivered in the 
prostate.
This study was extended to include determination of a correction factor to allow an 
independent radiation source (6 MV photon beam from a linear accelerator) to be used 
to obtain control readings for this relative dosimetric method.
The results showed these TLDs to be a promising in vivo dosimeter for prostate 
brachytherapy with potential errors in the order of 4%.  Their potential lies in the fact 
that they could detect and flag significant calculation errors in treatment plans, and 
they utilise equipment used routinely for external beam radiotherapy dosimetry in 
many treatment facilities, reducing the cost of implementing such a procedure.
Incorporation of these potential improvements into clinical use requires further work.  
As MR imaging involves a greater cost than CT imaging, it is important to be able to 
justify the potential benefit to the patient.  To commence using MR imaging routinely 
would require further analysis of data from a larger cohort of Oncologists to obtain a 
more statistically rigorous set of results than those presented in this thesis.  A trial use 
of LiF:Mg,Ti TLDs for in vivo dosimetry of prostate brachytherapy at St George 
Hospital is supported based on the results of this investigation along with data that has 
been published by Anagnostopoulos, Baltas, et al (2003) and Toye, Das et al (2008).  
If the results of such a trial are successful, it may be feasible to include this as a 
routine procedure for all prostate HDR brachytherapy patients.
3Chapter 1: General Introduction
The aim of this thesis was to investigate potential improvements on the two most 
important aspects of high dose rate (HDR) and pulsed dose rate (PDR) prostate 
brachytherapy – prostate definition and treatment delivery verification.  By 
investigating the use of magnetic resonance imaging of the prostate post-implant and 
analysing the results of TLD measurements in a phantom study, this thesis provides
an assessment of the benefits of incorporating these techniques into the current 
clinical environment, with a focus on the brachytherapy program at St George 
Hospital in Sydney, Australia.
1.1 Prostate Cancer
Prostate cancer is the most prevalent form of malignancy in the male population.  The 
American Cancer Society estimated over 30,000 deaths from the disease in the United 
States of America in 2005, and over 230,000 new diagnoses (Butler and Merrick 
2005).  Australian data suggests that prostate cancer accounted for 23% of all new 
cases of cancer in men in 2001 (McDermid 2005) and over 29% in 2005 (AIHW and 
AACR 2008).  Prostate cancer made up 13.8% of all male deaths from cancer in 2005 
(AIHW and AACR 2008).  The incidence of prostate cancer was stable in the 1980s, 
however there was a sharp rise in the number of cases diagnosed in the early 1990s as 
shown in Figure 1.1 (Tracey, Chen et al. 2006).  This upward trend is due to the 
availability of prostate-specific antigen (PSA) testing and therefore reflects a rise in 
diagnosis rather than incidence.  The incidence of prostate cancer in Australia is rising 
at a rate of 3.1% per year, however mortality from the disease is decreasing at a rate 
of 0.4% per year (AIHW and AACR 2008).  
4Figure 1.1 Incidence and mortality of prostate cancer in NSW 1972 – 2004. 
Reproduced with permission. (Tracey, Chen et al. 2006).
1.2 Treatment Options
There are various treatment options available for prostate cancer.  The decision of 
which option to choose is ultimately made by the patient, with recommendations from 
their urologist.  These recommendations will be made based upon various factors 
including stage and grade of the disease, as well as the general health and 
circumstances of the patient such as residential proximity to treatment facilities and 
work commitments.
Surgery (radical prostatectomy) and radiotherapy are the two main curative treatment 
techniques (Chin, Bullard et al. 2006).  There are various treatment regimes within 
radiotherapy including external beam monotherapy, external beam treatment with a 
High Dose Rate (HDR) brachytherapy boost, HDR monotherapy and Low Dose 
Rate (LDR) permanent seed implant.  Other treatment options for clinically localised 
prostate cancer include active surveillance and cryotherapy (Cox and Amling 2008).
There is no well-defined optimal treatment for localised prostate cancer; however 
disease control rates for intermediate- to high-risk disease are suboptimal when 
standard doses of external beam radiotherapy are delivered (Chin, Bullard et al. 
52006).  Increasing the dose with standard external beam radiotherapy increases the 
side effects.  Brachytherapy provides one option to escalate the dose whilst 
minimising toxicity (Chin, Bullard et al. 2006).
1.3 External Beam Radiotherapy for Prostate Cancer
External Beam Radiotherapy is an effective treatment option for men with early stage 
prostate cancer.  It can be used as a definitive treatment on its own, it may be used 
after radical prostatectomy to ensure that any tumour cells remaining are incapable of 
reproducing, or it may be used in combination with brachytherapy.  Treatments are 
generally given on a daily basis for a period of up to 6 or 7 weeks, and external beam 
therapy can be delivered as an outpatient treatment.  
A linear accelerator produces a high-energy photon beam, which is directed to the 
tumour site.  Sophisticated three-dimensional planning systems are used to plan the 
treatments.  The major disadvantage of external beam radiotherapy is that all the 
normal tissue between the skin surface and the tumour site receives a large dose of 
radiation.  
This form of radiotherapy treatment is well documented in literature (Perez, Brady et 
al. 2004), and will not be considered in any further detail within this thesis.
1.4 Brachytherapy
Brachytherapy is a special form of radiotherapy in which radioactive sources are 
placed at short distances from the target volume.  The sources may be placed within 
the target (interstitial), in a cavity close to the target (intracavitary) or on the surface 
of the patient (surface plaques - basal cell skin layer treatment or eye moulds).
The major advantage of brachytherapy over external beam radiotherapy is its ability 
to deliver a high dose of radiation to a confined region.  Brachytherapy sources have a 
rapid dose fall-off with distance from the source, as shown in Figure 1.2 below (Laub 
2002) allowing sparing of surrounding tissues.  This makes it ideal for the treatment 
of prostate tumours due to the proximity of radiosensitive organs such as the rectum 
and bladder. 
6Figure 1.2 Percentage Depth Dose curve for Ir-192 measured with a pinpoint 
ionisation chamber and diamond detector, compared with calculated curves, 
showing rapid dose fall-off with depth.  Reproduced with permission.
(Laub 2002).
Brachytherapy is a more invasive procedure than external beam radiotherapy, 
however it avoids high doses of radiation passing through normal healthy tissue to 
reach the target volume.  
1.5 Brachytherapy for Prostate Cancer
There are two major forms of brachytherapy currently in use for the treatment of 
prostate cancer.  These are LDR permanent seed implants and HDR afterloading.
Permanent LDR seed implants are becoming a more popular treatment option for low 
risk patients.  A high radiation dose can be delivered to the prostate with only a short 
hospital visit.  Accurate seed deployment within the prostate to match the pre-planned 
positions is difficult.  An HDR treatment plan is based on the actual positions of the 
needles rather than on a best case scenario as in the case of LDR planning, making it a 
more pliable technique.  HDR also has the advantage of being temporary.  The 
treatment is delivered quickly and no radioactive material is left in the patient.  
7Permanent seed prostate implants are well documented in the literature (Bice 2005; 
Butler and Merrick 2005; Lief 2005).
HDR brachytherapy is commonly used as a boost to external beam radiotherapy.  This 
thesis will focus on the HDR technique.  It involves the insertion of needles through 
the perineum into the prostate using transrectal ultrasound guidance.  An iridium-192 
source contained in a remote afterloading device is then programmed to dwell at 
various positions within each needle for a pre-determined time to create a three-
dimensional dose distribution throughout the prostate.  The blue isodose cloud in 
Figure 1.3 below is a typical dose distribution for a prostate treatment.  The prostate is 
shown in red under the translucent 100% isodose cloud, and the rectum is shown as 
the pink wireframe.  This image was created in the PLATO brachytherapy planning 
system – a commercially available planning software package from Nucletron Pty Ltd
(Australia).  
Figure 1.3 Three-dimensional view of a typical HDR prostate dose cloud –
PLATO brachytherapy planning system (Nucletron Australia Pty Ltd). 
Remote afterloading was introduced with HDR in the late 1980s.  The Ir-192 source is 
located in a shielded afterloader, which is operated from outside the room.  This 
technique has replaced manual loading, and it minimises the radiation dose received 
8by staff and provides significantly better control of where the radiation dose is 
delivered (Ouhib 2005).  This technique also provides increased flexibility to optimise 
where the radiation is delivered.  Afterloading has removed the constraint of using a 
source with fixed activity and location, allowing for the reduction of occurrence of 
regions of excessive or insufficient dose.  This leads to a reduction in normal tissue 
toxicity (Hoskin 2001).
Prostate cancer differs from other types of cancer in that the prostate cancer cells 
reproduce slowly.  The rate of reproduction is comparable to healthy tissue cells 
(Pickett and Pouliot 2005).  Successful treatment can therefore only be achieved if a 
higher dose of radiation is delivered to the prostate than to the surrounding normal 
tissue.  HDR brachytherapy can deliver a highly conformal dose distribution in a 
small number of fractions, making it ideal for the treatment of prostate cancer (Pickett 
and Pouliot 2005).  
The total dose prescribed to the prostate and the fractionation (amount of dose 
delivered per session) varies between centres.  Table 1.1 (Vicini, Kini et al. 1999; 
Ouhib 2005) lists various fractionation schedules from various treatment centres 
around the world.  All centres included in this list perform HDR prostate 
brachytherapy as a boost to external beam radiotherapy.
HDR brachytherapy is frequently used in conjunction with hormone (androgen 
deprivation) therapy.  The hormones reduce the prostate in size and make the prostate 
cancer cells more sensitive to radiation, thereby making the treatment more effective 
(Butler and Merrick 2005).
For HDR brachytherapy to be most effective, it requires accurate dose planning, 
followed by accurate and verifiable delivery (Williamson, Ezzell et al. 1994).  These 
issues will be discussed below and will be the main focus of this thesis. 
9Table 1.1. External beam in combination with brachytherapy - treatment 
regimes used in published studies.  This data is collated from Vicini, Kini et al.
(1999) and Ouhib (2005) based on references therein.
External Beam 
Dose
Brachytherapy Regime
Total Brachytherapy 
Dose
36 Gy 6.0 Gy x 3 fractions (2 insertions) 36 Gy
39.6 Gy 6.0 Gy x 4 fractions 24 Gy
45 Gy 5.5 Gy x 3 fractions 16.5 Gy
45 Gy 35 Gy 35 Gy
45.6 Gy 5.5 – 6.5 Gy x 3 fractions 16.5 Gy – 19.5 Gy
46 Gy
5.5 Gy x 3 insertions
6.0 Gy x 3 insertions
6.5 Gy x 3 insertions
16.5 Gy
18 Gy
19.5 Gy*
50 Gy 4.0 Gy x 4 fractions 16 Gy
50 Gy 10 Gy x 2 fractions 20 Gy
50 Gy 10.2 Gy x 2 insertions 20.4 Gy
50 Gy 15 Gy x 2 insertions 30 Gy
50.4 Gy 3.0 – 4.0 Gy x 4 fractions 12 Gy – 16 Gy
* This was the fractionation scheme used at St George Hospital at the time the 
patients used in this study were treated.
1.6 HDR Prostate Brachytherapy Planning
Accurate treatment of the prostate using HDR brachytherapy requires accurate 
definition of the target followed by a method to accurately expose the target to the 
prescribed dose of radiation whilst avoiding other surrounding structures (Williamson, 
Ezzell et al. 1994; Hoffelt, Marshall et al. 2003).
Cladwell and Mah (2005) said that “precise and accurate definition of the target 
volume for radiation treatment is essential to maximise the probability of both tumor 
coverage and normal tissue sparing.”  This is a statement that provides the focus for 
the imaging component of this thesis.
10
Most modern brachytherapy software allows the user to view Computed Tomography 
(CT) or Magnetic Resonance (MR) images on the screen, and mark the target volume 
and critical structures (such as rectum, urethra, bladder and seminal vesicles) as well 
as the implanted needles.  The software utilises detailed information on the 
radioactive source structure, design and activity in its algorithm to calculate dose.  
Unlike planning systems used for external beam treatments, most brachytherapy 
planning systems do not utilise density information from the CT scans to calculate 
radiation dose.  They assume that the tissues in and around the implant are water-
equivalent (Rivard, Coursey et al. 2004).  The brachytherapy systems are based on 
geometry.  Further corrections are applied such as source anisotropy corrections and 
radial dose functions.  These corrections are defined in detail in the AAPM 
Radiation Therapy Committee Task Group No. 43 and its subsequent update (Nath, 
Anderson et al. 1995; Rivard, Coursey et al. 2004).  
The brachytherapy planning system is used to represent the prescribed dose to the 
prostate and there are various methods available to optimise the three-dimensional 
distribution of this dose (Ezzell 2005; Pouliot, Lessard et al. 2005).  By optimising, 
the planner can achieve an accurate conformal plan, without over-radiating the critical 
structures. There are a variety of systems commercially available for the planning of 
HDR prostate brachytherapy treatments.  
It has been documented that an accurate representation of the prostate volume is 
crucial for successful treatment (Hoffelt, Marshall et al. 2003).  Citrin, Ning et al. 
(2005) indicate that MRI provides superior visualisation of the prostate and 
surrounding tissues in comparison to other imaging modalities, improving the 
accuracy of defining the target volume for a prostate treatment.  Whereas CT images 
provide a map of electron density as measured by photon attenuation, MR images 
provide information on proton density as well as the freedom of hydrogen-containing 
molecules to rotate.  They also give information on the proportion of water contained 
in different body-fluid compartments (Leach 1988).  These properties make MR 
imaging better for soft-tissue differentiation than CT imaging (Cladwell and Mah 
2005).
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Despite this, CT imaging remains the modality of choice for most radiotherapy 
techniques (Carey, 2005).  This is largely due to its wider availability and lower cost 
compared with MR imaging (Sistrom and McKay 2005).
1.7 Toxicity in Prostate Brachytherapy
Exposing normal tissue to radiation can be detrimental to normal function of that 
tissue due to the damage imparted to the DNA (Kunkler 2003).  There are several 
critical structures in close proximity to the prostate, to which the radiation dose must 
be limited.  The urethra and rectum are two of the most important structures in this 
regard.  
The urethra runs from the base of the bladder, through the middle of the prostate and 
out via the penis.  Typically, HDR treatments of the prostate are designed to treat the 
entire prostate, so the prostatic urethra inevitably receives a high dose of radiation –
often higher than the prescribed dose to the prostate.  Urethral strictures are a 
common form of urethral toxicity in this form of treatment (Butler and Merrick 2005).  
The rectum runs posterior to the prostate and frequently approaches to within 1 cm of 
the prostate.  Proctitis is a common late effect of over-exposure of the rectum to 
radiation (Butler and Merrick 2005).  
It is important to ensure the dose to the critical structures is kept as low as possible.  
Verification of the location, size and shape of the target region is necessary for 
successful treatment.  In addition, the regions where radiation delivery is not desirable 
must also be clearly defined.  Verification of accurate delivery is the next step to 
ensure the best possible outcome for the patient.
1.8 In vivo Dosimetry
It is common practice in external beam radiotherapy to use a form of in vivo
dosimetry to verify the radiation dose received by critical structures.  The European 
Society for Therapeutic Radiology and Oncology (ESTRO) show the importance of 
verification of the absorbed dose delivered during a radiation treatment (Van Dam and 
Marinello 2006).  They indicate that in vivo dosimetry is useful to detect errors in 
individual patients, errors in core procedures, to evaluate the quality of specific 
12
treatment techniques and to evaluate the dose delivered in situations where the dose 
calculation is inaccurate or not possible (Van Dam and Marinello 2006). In vivo
dosimetry is not common practice in brachytherapy as it is in external beam 
radiotherapy, and few centres currently utilise any form of in vivo dosimetry for 
brachytherapy.  Often in brachytherapy treatments, higher doses of radiation are 
delivered per fraction than in external beam treatments.  A method to verify the 
radiation dose is therefore justified, and various detectors have been proposed for this 
purpose, however none are currently in routine use.  
Thermoluminescent dosimeters (TLDs) come in various materials, shapes and sizes.  
This project will consider lithium fluoride TLDs doped with magnesium and titanium 
(LiF:Mg,Ti) for use in prostate brachytherapy.  This material has well-established 
characteristics and has been in use for external beam radiotherapy in vivo dosimetry 
measurements for many years.  
Other dosimeters currently under investigation by other research groups for use in 
brachytherapy in vivo dosimetry include Metal Oxide Semiconductor – Field Effect 
Transistors (MOS-FETs) (Cygler, Saoudi et al. 2006), lithium fluoride TLDs doped 
with magnesium, copper and phosphorus (LiF:Mg,Cu,P) (Duggan 2002) and optical 
fibre dosimeters (Lambert, McKenzie et al. 2006).  Further detail on these dosimeters 
is presented in Section 2.3.2.
1.9 Aims and Outline of the Thesis
The aim of this thesis as stated in the opening paragraph was to investigate potential 
improvements on the two most important aspects of prostate HDR and PDR
brachytherapy – prostate definition and treatment delivery verification.  
The issue of prostate definition was addressed via the introduction of the use of MR 
imaging into prostate brachytherapy planning.  This included a study of the ability to 
delineate the prostate and critical structures consistently, and the ability to accurately 
define the needle positions.  It also included a study of the effect of the alternative 
prostate and critical structure dimensions as determined by the different imaging 
modalities on the dosimetric outcomes for the patients.
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The issue of accurate treatment delivery verification was addressed by adapting an 
existing method for in vivo dosimetry in external beam radiotherapy to verify the dose 
delivered in prostate HDR brachytherapy.  This was carried out as a phantom study
using a standard thermoluminescent material and was aimed at determining the 
suitability of this material for routine verification of patient dose, with particular focus 
on establishing a consistent conversion factor to allow the use of an independent 
control dose to TLDs exposed to radiation from a 6 MV linear accelerator.
Chapter 2 is a literature review discussing the imaging techniques examined within 
this thesis, as well as a review of the information available on the thermoluminescent 
dosimeters (TLDs) used in this project.  It also includes a summary of recent findings 
reported in the literature relevant to imaging of the prostate and in vivo dosimetry for 
brachytherapy.
Chapter 3 is a study investigating the use of MRI in prostate HDR brachytherapy.  
This chapter contains detail on the materials and methods used in this project.  It
contains the results and a discussion of this study involving the comparison of the use 
of CT and MRI in prostate HDR brachytherapy planning.  
Chapter 4 is a study developing and investigating the use of a standard 
thermoluminescent material for in vivo dosimetry of prostate HDR brachytherapy.  
This chapter contains detail on the materials and methods used in this project.  It also 
contains the results and a discussion of the phantom study investigating the use of 
LiF:Mg,Ti TLDs for verifying patient dose in prostate HDR and PDR brachytherapy, 
including the measurement of a conversion factor to account for measurement of 
control doses on a linear accelerator.
Chapter 5 provides conclusions and recommendations based on the results presented 
in Chapters 3 and 4.
Items highlighted throughout the thesis in bold type are defined in Appendix A –
Glossary.
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Chapter 2: Literature Review
2.1 HDR Prostate Brachytherapy
Adenocarcinoma of the prostate is currently the most common cancer diagnosed in 
men (Nori and Moni 1997; D'Amico, Cormack et al. 1998; Menard, Susil et al. 2004; 
McDermid 2005).  The advent of prostate-specific antigen (PSA) testing has led to 
earlier diagnosis of prostate adenocarcinoma in younger men (Nori and Moni 1997).  
Late complications of the treatment technique used must be considered carefully as 
this cohort of early-diagnosed men have a much longer survival rate (Nori and Moni 
1997).  Quality of life is also more important for these younger men, including issues 
such as urinary and rectal function as well as erectile function (Butler and Merrick 
2005).
External beam radiotherapy is regarded as the gold standard treatment modality for 
patients with locally advanced prostate cancer.  The recurrence rates after this form of 
treatment are quite high.  Some reports indicate recurrence rates of up to 60% 
(Martinez, A., Gonzalez et al. 1995).  Standard external beam treatments for prostate 
cancer deliver a total of around 70 Gy in fractions of 2 Gy per day, 5 days per week or 
9 days per fortnight (TROG 2003).  This treatment fractionation schedule raises 
concerns with internal organ motion from day to day, as well as setup inaccuracies 
over 35 separate treatments.  To overcome this, a margin is usually added around the 
prostate.  This results in the delivery of large doses to non-cancerous tissues around 
the prostate (Martinez, A., Gonzalez et al. 1995).  Doses in excess of 70 Gy delivered 
as external beam radiotherapy can result in an increase in genitourinary and 
gastrointestinal side effects (Chin, Bullard et al. 2006).  Currently available options to 
increase the total dose while minimising toxicity include intensity-modulated 
radiation therapy (IMRT) and brachytherapy (Chin, Bullard et al. 2006).
For early-stage prostate cancer, the best method of obtaining a conformal treatment is 
to insert radioactive sources directly into the prostate in the form of temporary 
placement of a radioactive source in implanted needles (HDR brachytherapy), or 
permanent seeds (Grimm, Blasko et al. 1996), however these forms of treatment are 
not appropriate for all forms of the disease.
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HDR brachytherapy has the advantages of being able to deliver conformal high doses 
of radiation to a precisely localised target, rapid dose fall-off and minimal target 
movement during the treatment.  Both the position and the dwell time along the 
implanted catheters can be altered to obtain a very conformal dose distribution, and 
this also allows greater sparing of nearby organs at risk, particularly the urethra and 
rectum (Chin, Bullard et al. 2006).
The use of remote afterloading with Ir-192 HDR for prostate treatment was 
introduced in the late 1980s.  HDR has been used for more than 40 years to treat other 
anatomical sites.  The technique for HDR and Pulsed Dose Rate (PDR) treatment of 
the prostate is identical.  Needles are inserted in the operating theatre under trans-
rectal ultrasound and fluoroscopic guidance.  A template is usually fixed to the 
perineum, through which the needles are inserted through the prostate.  Most centres 
use CT-based planning, so the patient must be taken to the CT scanner after the 
implant procedure.  CT markers are commercially available for plastic needles, and 
these allow visualisation of the first possible dwell position of each needle.  The 
Radiation Oncologist defines the target volume as well as the critical structures or 
organs at risk.  The urethra, rectum and bladder are commonly defined as critical 
structures in the planning system.  The afterloader is programmed to move the Ir-192 
source in specified steps within each needle (Ouhib 2005).
Various different fractionation regimes have been used with HDR brachytherapy at 
many treatment centres around the world.  Generally, it is used as a boost to external 
beam radiotherapy treatments (Vicini, Kini et al. 1999), but has also been used as a 
monotherapy technique (Martinez, A. A., Pataki et al. 2001; Martin, Baltas et al. 
2004). However, brachytherapy as a monotherapy technique is usually reserved for 
lower risk disease, and is still considered investigational (Chin, Bullard et al. 2006).  
At St George Hospital in Sydney, Australia, at the time of the measurements 
presented in this thesis, standard combined brachytherapy and external beam 
treatment delivered 19.5 Gy in three fractions of brachytherapy (each fraction 
separated by a minimum of six hours – total treatment completed within 36 hours), 
followed by 46 Gy of external beam radiotherapy in 2 Gy fractions over 23 days.  
This external beam component of the treatment commenced three weeks after the 
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brachytherapy implant.  The brachytherapy component was delivered using a PDR
Iridium-192 (Ir-192) source.  
A non-exhaustive list of other treatment regimes using Ir-192 in various studies 
around the world was given in Table 1.1. (Vicini, Kini et al. 1999; Ouhib 2005).
The minimum time between fractions is usually 6 hours.  This is due to the 
radiobiological effects of the radiation, to allow sufficient repair and re-oxygenation 
of late-responding normal tissues which have been damaged by the radiation exposure
(Brenner, Dale et al. 2001).  Unless specified as separate insertions, the fractions 
given in Table 1.1 are all delivered during one insertion (implant).
2.2 Imaging of the Prostate
Imaging of the prostate began with the introduction of the trans-rectal ultrasound in 
the early 1970s.  In the subsequent decades, technological developments have 
introduced various other imaging modalities including CT and MRI (Carey 2005).  
These modalities are discussed in this section with particular focus on their use in 
brachytherapy.
2.2.1 Issues in prostate imaging 
Improvements in radiotherapy techniques have led to the requirement for more 
accurate delineation of the location and extent of prostate cancer (Carey 2005).  The 
main imaging modalities currently available for imaging the prostate are transrectal 
ultrasound, CT and MR. (Carey 2005).
Ultrasound is mostly used for needle placement.  It can be used to define the 
peripheral zone of the prostate reliably, which is the location in which most prostate 
cancers originate (Carey 2005).  
CT is the technique most widespread for planning radiation treatment.  Despite this, 
CT does not show any tumour within the prostate gland, cannot define prostate 
margins with great accuracy, and overestimates the true gland volume (Carey 2005).
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MR imaging of the prostate provides the most accurate information about the anatomy 
and location of tumour within the prostate gland (Menard, Susil et al. 2004).  It also 
exhibits good correlation with both ultrasound and pathologic evaluation of the 
prostate (Dubois, Prestidge et al. 1998).  The high incidence of prostate cancer and the 
high cost of MRI combine to make this imaging technique less economically viable 
for healthcare facilities (Carey 2005).
2.2.2 Computed Tomography 
2.2.2.1 History and Theory
Computed Tomography (CT) scanners produce thin cross-sectional images of the 
human body.  CT is considered a non-invasive radiographic technique, and the 
scanner collects a large number of x-ray attenuation measurements, which are then 
used to reconstruct the cross-sectional image (Van Dyk and Taylor 1999).  
CT scanners first became available in the early 1970s.  Since that time, the technology 
has advanced significantly.  Van Dyk and Taylor (1999) provide an overview of the 
historical development of CT scanners, and Cladwell and Mah (2005) provide an 
update of more recent developments.  
CT images provide electron density information, however for brachytherapy 
applications, this information is not utilised for dosimetry calculations – only in the 
generation of the images.
2.2.2.2 CT in Brachytherapy
The first study using CT for prostate brachytherapy was published in the early 1990s.  
This was for seed post-implant dosimetry carried out at Memorial Sloan-Kettering 
Cancer Centre.  Today, CT is still the most utilised imaging tool for post-implant 
dosimetry due to its relatively low expense and good visualisation of the seeds (Bice 
2005).  
It was not until the late 1990s that CT was first used for HDR brachytherapy planning.  
Prior to this, the common planning procedure was based on ultrasound images of the 
prostate before and after the implantation.  Martin, Kolotas et al. (1999) were one of 
the first groups to utilise CT based planning for HDR prostate brachytherapy.  They 
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found that the significant advantages in using CT imaging to plan the treatment were 
the ability to reconstruct non-parallel needles, define an individual planning target 
volume, optimise the dose distribution and evaluate the quality of the implant.
Also in 1999, Kolotas, Baltas et al. (1999) published their study on the use of CT for  
interstitial brachytherapy.  They report the advantage of CT-based brachytherapy 
planning as allowing anatomy-based planning as opposed to applicator-based 
planning traditionally used in brachytherapy treatments.  This study examined various 
anatomical regions including the brain, pelvis and lymph nodes in the neck.  Results 
were compared to reconstruction using radiographs, and the CT reconstruction was 
found to give equivalent accuracy in a much shorter time.
Pouliot, Lessard et al. (2005) also report on this shift to anatomy based planning due 
to the introduction of 3 dimensional imaging techniques.  It was previously assumed 
that if the dose distribution covered the catheters, then it should also cover the 
anatomy.  This resulted in the treatment typically of a cylindrical-shaped prostate, 
causing significant overdosage of normal tissues surrounding the prostate.
2.2.3 Magnetic Resonance Imaging (MRI)
2.2.3.1 History and Theory
Nuclear magnetic resonance (NMR) was proposed as a method for detecting tumours 
around 1971, many years before it became the 3-dimensional imaging tool in use 
today.  MRI was developed and arrived on the scene approximately 6 to 10 years after 
CT, which had already been established as the primary imaging modality for 
radiotherapy treatments (Peters, Slomka et al. 1999).
Peters, Slomka et al. (1999) provide a thorough outline of magnetic resonance 
imaging.  
Despite the advantages of MR over CT in some areas, it is not commonly used as a 
replacement for CT in radiotherapy planning.  Reasons for this include the lack of 
electron density information, susceptibility to distortion and the lack of software 
availability to integrate and manipulate MR images within planning systems (Peters, 
Slomka et al. 1999).
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2.2.3.2 MRI in Brachytherapy
Various studies have been published on the use of MRI for brachytherapy planning of 
the prostate.  These studies contain information on both permanent seed implantation 
and HDR prostate brachytherapy procedures.  
Menard, Susil et al. (2004) published an investigation concerning MRI-guided HDR 
prostate brachytherapy.  They reported that MRI provided “superior visualisation of 
the prostate and surrounding anatomy, making it the modality of choice for imaging 
the prostate gland”.  
D'Amico, Cormack et al. (1998) used MRI to perform real-time MR-guided seed 
implantation of the prostate.  This was studied as an alternative technique to the 
standard 2-dimensional transrectal ultrasound guided technique.  The advantage of 
this technique was that the imaging did not interfere with the prostate shape.  A trans-
rectal ultrasound probe may distort the prostate and therefore cause a change in the 
geometric distribution of seeds when removed, resulting in a different dose 
distribution to that planned.  This study reported that this technique provided the 
ability to achieve the MR-planned, optimised dose-volume histogram profiles to the 
clinical target volume and other structures with minimal acute morbidity.  No 
discussion of the accuracy of the MR imaging was included.
McLaughlin, Narayana et al. (2002) conducted a comparison of MRI pulse sequences 
in defining prostate volume after permanent seed implantation.  They compared T1-
weighted, T1-weighted fat saturation and T2-weighted axial MRI studies on a total of 
45 patients.  This study reported that the T2-weighted MR images gave a consistently 
smaller prostate size than the other methods.  It was suggested that this was due to the 
superior prostate definition provided by the T2-weighted technique, particularly with 
interfaces between the prostate and other structures including the membranous 
urethra, apex, and anterior base/bladder and posterior base/seminal vesicle interfaces.
Susil, Camphausen et al. (2004) proposed a system for the use of a 1.5 Tesla MRI 
scanner for prostate HDR brachytherapy.  They reported placement of 14 or 15 HDR 
brachytherapy catheters under MR guidance, taking 2 hours for each of the first two 
patients, then 1.5 hours on subsequent patients.  The patient was placed on his side in 
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the scanner, in the left lateral decubitus position.  The MR images could then be used 
to create an optimised treatment plan.  This technique would involve having an MRI 
scanner in the operating theatre, and is therefore not an option for many treatment 
centres in Australia.  
Some investigations have also been carried out on the use of magnetic resonance 
spectroscopy imaging (MRSI) for planning prostate brachytherapy treatments.  
Zaider, Zelefsky et al. (2000) proposed the use of MRSI to distinguish between 
regions of cancerous and non-cancerous prostatic tissue.  This information could then 
be used to escalate the dose to intraprostatic tumour deposits using radioactive seed 
brachytherapy.  The proposed system, which included an integer-programming 
technique to optimise the seed distribution, achieved a minimum dose of 120% of the 
prescribed dose to MRS positive voxels, with relative sparing of surrounding normal 
tissue.  Only one patient was used in this study.
A similar study was published two years later (DiBiase, Hosseinzadeh et al. 2002).  
Fifteen patients were recruited in this study and the data was used for fourteen of 
these patients’ treatment plans.  The reason for the one patient whose MRSI data 
could not be used was the presence of multifocal disease, making focal boosts 
impractical.  This study reports boosts of 130% of the prescribed dose in the focal 
regions, with urethral and rectal doses within normal limits.  MRSI is a potential 
method of improving the therapeutic ratio in prostate seed brachytherapy and 
similarly in HDR brachytherapy.  These MRSI studies demonstrate a further 
advantage of using MR for the planning of prostate brachytherapy treatments.
Mizowaki, Cohen et al. (2002) also suggested the use of MRSI as a further advantage 
of MR imaging for prostate brachytherapy. They similarly report that functional 
imaging may be utilised to assist in determining the location of the cancer cells within 
the prostate.  This could allow for dose escalation in certain regions of the prostate 
where the cancer cells are most prolific, however they report that MRSI involves the 
use of an endorectal balloon receiver coil that distorts the prostate.  Further work 
would be required to establish this procedure as routine for prostate brachytherapy 
planning.
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Citrin, Ning et al. (2005) reported on the use of MRI alone for HDR prostate 
brachytherapy treatment planning.  The issues they addressed included correction and 
verification of spatial distortion (caused by non-uniform magnetic fields, and 
correctable using commercially available software), correction of the DICOM (Digital 
Imaging and Communications in Medicine) header to allow MR image transfer into 
the planning system, and determination of the first dwell position based on 
visualisation of the void created by the needle.  Their results showed that it was 
possible to complete a prostate HDR treatment plan on MRI images alone.
No literature was found discussing the results of the use of MRI in radiotherapy or 
brachytherapy planning in terms of improved survival.
2.2.4 Comparison Studies
Various comparison studies between CT and MR imaging of the prostate for 
brachytherapy procedures have been reported in the literature.  No specific 
comparison studies were found for HDR brachytherapy imaging of the prostate.  The 
publications refer to permanent seed brachytherapy, however the same general 
conclusions can be made for imaging of the prostate for HDR brachytherapy.  
Dubois, Prestidge et al. (1998) reported on intraobserver and interobserver variability 
of MR and CT derived prostate volumes for 41 permanent brachytherapy seed 
implants of the prostate.  They reported that transrectal ultrasound could adequately 
visualise the prostate gland, however the seeds caused significant artefact and the 
position of the ultrasound probe may have prevented accurate source localisation.  CT 
and MR imaging had the advantage of being non-invasive.  CT was excellent for 
visualising the seeds, and equally the needles used for HDR brachytherapy when a CT 
marker was used (refer to Section 3.1.1.7), however the prostate was not clearly 
delineated.  It was reported that MR imaging correlated closely with the volume of the 
prostate both with ultrasound imaging and pathologic evaluation.
This paper reported a significantly higher variation in prostate volume between 
observers for CT imaging (8.5 cm3 ± 9.74) compared with MR imaging (1.9 cm3 ±
11.7) at a similar expense.  The volumes delineated on the MR images were also more 
consistent from an intraobserver’s perspective.  Observer 1 CT variability was 2.9% ± 
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29.4, and MR variability was 3.2% ± 8.4.  Observer 2 CT variability was 6.4% ± 15.5, 
and MR variability was 1.2% ± 1.2.
Crook, Milosevic et al. (2002) also reported on interobserver variability in prostate 
volume for permanent seed brachytherapy.  They used MRI-CT fusion as the gold 
standard for prostate-edge identification.  Prostate volumes on CT images alone were 
generally 25 – 40% larger than on ultrasound or MRI in this study.  This was 
reportedly due to the difficulty in distinguishing the prostate from the surrounding 
muscles and venous plexus.  The rationale for this particular study stemmed from the 
fact that if the prostate volume was inaccurate, then dosimetry of the brachytherapy 
implant would be imprecise and any dose-response relationships would be less 
apparent.  Brachytherapy dose calculations are based on geometry of the implant and 
anatomical structures.  The steep dose gradient makes dosimetry around this fall-off 
difficult to achieve with great accuracy, so if the volume is imprecise, there may be a
significant difference in dose delivered.  This Group found that CT/MRI fusion was 
the ideal imaging tool for determining the correct spatial relationship between the 
seeds and target contours, as the accuracy of the seed location was best determined on 
the CT images, whereas the prostate was delineated more clearly and reproducibly on 
the MR images (based on interobserver differences).
Various other publications including Polo, Cattani et al. (2004); Solhjem, Davis et al. 
(2004); Carey (2005); Miquel, Rhode et al. (2006) all report the same findings that 
CT is inadequate for accurately defining the prostate volume and indicate that MRI is 
a better method for accurate prostate definition.  These authors all focus on seed 
brachytherapy implant imaging except for Carey (2005), who examines the imaging 
of prostate cancer in general. 
2.2.5 Image Fusion
Polo, Cattani et al. (2004) reported on the fusion of MR and CT images for permanent 
seed dosimetric analysis, comparing the dosimetric results with those generated on a 
CT alone.  They noted significant differences in the dose level to the prostate with 
each method of imaging, and the volume of the prostate was on average 36% greater 
using CT alone compared with CT-MRI fusion.  This result was dependent on the 
person defining the volume on the images and applies equally to HDR brachytherapy 
as well as permanent seed impants.
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Miquel, Rhode et al. (2006) reported on a combined x-ray and MR imaging technique 
under development, using MRI fused with x-ray images.  This technique may become 
more useful with further development for permanent seed post-implant dosimetry 
purposes, however its use in HDR brachytherapy is further limited by the time it 
would take to reconstruct the position of the needles.
No specific studies related to fusion of images for HDR brachytherapy were found.
24
2.3 In vivo Dosimetry
2.3.1 Thermoluminescence Dosimetry
2.3.1.1 History and Theory
Kron (1995) provides a thorough history of thermoluminescence dosimetry in 
medicine.  A brief outline will be reported here.  
The phenomenon of thermoluminescence has been known for hundreds of years.  
Shortly after the discovery of ionising radiation, Marie Curie noted the 
thermoluminescence of calcium fluoride after exposure to radium.  Further work was 
undertaken in 1925 by F. Wick to study the effect of X-rays on thermoluminescent 
materials (Kron 1995).
It was a further 20 years before J. Randall and M. Wilkins formulated a theory of 
TLD, based on the interpretation of glow curves.  This is still the basis for the current 
understanding of TLD (Kron 1995).  An article in 1953 by F. Daniels et al reports on 
the use of lithium fluoride (LiF) TLDs for clinical measurements.  Daniels was also 
the first to establish the annealing of LiF at 400°C, a method still in use today (Kron 
1995).
Towards the end of the 1950s, the purity of the LiF was increased, resulting in a 
decline in the ability of the material to measure radiation dose.  J. Cameron 
demonstrated the importance of the impurities – particularly the magnesium.  His 
work led to the development of the TLD material used in this project – LiF:Mg,Ti 
(TLD100 – lithium fluoride doped with magnesium and titanium) (Kron 1995).  
In the following years, research was carried out to test different forms of the TLD 
material.  By incorporating LiF powder into a Teflon coating, the dosimeters could be 
made to any shape or form.  Research also continued to improve the tissue-
equivalence of the TLD material (Kron 1995).  
TLD is still one of the most important techniques for assessing ionising radiation 
doses, both for evaluation of new diagnostic techniques as well as for in vivo
dosimetry on real patients.  Its uses extend into radiation protection and environmental 
monitoring (Kron 1995).
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A detailed theory of thermoluminescence is complex, and beyond the scope of this
project.  Duggan (2002) lists various publications such as McKinlay (1981) and 
McKeever (1995) that are dedicated to this complex theory.  Kron (1994) published a 
simplified theory, which will be discussed here only to provide sufficient information 
for an understanding of the use of TLDs in brachytherapy.
A thermoluminescent (TL) crystal is usually a non-conducting crystal.  At room 
temperature, all electrons reside in the valence band.  By exposing the crystal to 
ionising radiation, some electrons gain enough energy to be promoted into the 
conduction band.  In a perfect crystalline structure, after exposure to radiation, the 
electrons in the conduction band would drop back down to the valence band, emitting 
energy in the process.  TL crystals have imperfections that trap a small percentage of 
the electrons in an energy state between the conduction and valence band.  The energy 
gap between conduction band and the trap is only a few electron volts.  The number of 
electrons trapped is a function of the intensity of the radiation (Kron 1994).  
The probability of the electrons gaining enough energy to escape from the trap 
depends on the depth of the trap as well as the temperature.  If the temperature is 
sufficiently high, the trapped electron may gain enough energy to move back up to the 
conduction band.  It will then spontaneously fall back to the valence band, 
recombining with a hole and emitting visible light in the process (Kron 1994).  The 
basic process involved can be seen in Figure 2.1 below (Kron 1999).
Figure 2.1: Schematic diagram of thermoluminescence process. 
Reproduced with permission. (Kron 1999).
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Most TL materials have various trap types, with differing energy gaps to the 
conduction band.  They will therefore empty at different temperatures.  This can lead 
to a complicated function of light intensity vs temperature, known as a glow curve
(Kron 1994).  Figure 2.2 is a typical glow curve for LiF:Mg,Ti, the material used in 
this project (Kron 1999).  LiF:Mg,Ti has at least eight different energy traps, and 
therefore eight distinct peaks in the glow curve (only six are shown in Figure 2.2 – the 
other peaks occur at higher temperatures) (Kron 1994).
The intensity of the visible light emitted is related to the intensity of ionising radiation 
the TL material was exposed to.  It is also influenced by various factors including the 
geometry of the material, the thermal and radiation history of the material, the time 
between irradiation and readout, total radiation dose, dose rate and radiation quality.  
TLD is therefore most suitable for relative dosimetry and not absolute dosimetry
(Kron 1994).
To read the amount of light emitted by the TLD, a photo multiplier tube is used.  The 
TLD is exposed to a constant heating rate.  The light recorded by the photo multiplier 
tube is associated with the temperature at which it was emitted by the TLD and this 
information is combined to create a glow curve (Section 2.3.1.2.1) (Kron 1994).  
2.3.1.2 Properties of LiF:Mg,Ti
Kron (1994) describes the properties of the most commonly used clinical TL material, 
LiF:Mg,Ti.  A brief summary of this is included here to provide sufficient information 
for an understanding of the use of LiF:Mg,Ti in brachytherapy.
2.3.1.2.1 Glow Curves
A typical glow curve for LiF:Mg,Ti is shown in Figure 2.2 (Kron 1999).  Seven 
distinct glow peaks can be observed for LiF:Mg,Ti when read up to 300°C.  Each of 
these is associated with different traps.  Peaks IV and V are typically used for 
evaluation of dose.  The higher peaks generally only occur when high doses are 
delivered, and are usually not evaluated (Kron 1994).
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Figure 2.2: Typical glow curve for LiF:Mg,Ti.
Reproduced with permission (Kron 1999).
Most TLD readers in use for clinical measurements heat up the TLDs at a relatively 
fast rate.  This keeps the readout time short, but results in the merging of two or more 
peaks into one (Kron 1994).
Following radiation exposure, the TLD can be annealed at a low temperature (100°C) 
for a short time to reduce the effect of the lower temperature peaks on the reading
(Kron 1994).
2.3.1.2.2 Fading
There is a possibility that some electrons can gain enough energy at room temperature 
to escape from their traps.  The smaller the energy gap between the trap and the 
conduction band, the more probable it is that this spontaneous emission of light will 
occur.  This will reduce the TL signal and is therefore known as fading (Kron 1994).  
The half life for the various traps in LiF:Mg,Ti at room temperature vary from a few 
minutes to several years.  Peaks IV and V have half lives of approximately 10 years 
and 80 years respectively.  This equates to fading of the order of 5% over 12 weeks.  
Exposure of the crystals to light, particularly UV components, can increase the 
amount of fading (Kron 1994).
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2.3.1.2.3 Linearity
At very low doses, LiF:Mg,Ti overestimates the dose.  The response has been 
reported to be linear above approximately 10-5 Gy, which is around the detection limit 
of the material (Kron 1994).  The response is linear up to doses of around 1 – 3 Gy.  
Beyond this level, the sensitivity of the dosimeters increases.  This phenomenon is 
known as supralinearity.  There is approximately 5% supralinearity at 3 Gy, resulting 
in a higher dose being reported.  At very high doses (100-1000 Gy), the sensitivity 
decreases again due to irreversible radiation damage (Kron 1994).  This trend can be 
seen in Figure 2.3 (Kron 1999).
Figure 2.3: Dose response of LiF:Mg,Ti. 
Reproduced with permission. (Kron 1999).
The effect of supralinearity can be reduced by irradiating a control set of TLDs to a 
known dose of the same magnitude as the dose to be measured, at the radiation quality 
in question (Kron 1994).  
2.3.1.2.4 Annealing Cycles
A full anneal cycle must be carried out after each readout, prior to using the TLDs
again.  This restores the sensitivity of the TL material by removing any residual 
electrons from their traps (Kron 1994).  Various anneal cycles have been proposed for 
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LiF:Mg,Ti.  These include annealing to 400°C for 1 hour only, 1 hour at 300°C 
followed by 16 hours at 80°C, 1 hour at 400°C followed by 24 hours at 80°C, 1 hour 
at 400°C followed by 2 hours at 100°C (Horowitz 1990).  The pre-irradiation anneal 
cycle suggested by the manufacturer (Thermo Electron Corporation, Canada) is 1 
hour at 400°C followed by 2 hours at 100°C.  It has been noted that there is a 
significant increase in sensitivity at high doses of radiation (>1 Gy) if significantly 
lower temperatures (for example 300ºC) are used for the high-temperature anneal
(Horowitz 1990).  However, no change in sensitivity was found when the anneal 
temperature was between 360ºC and 440ºC (Horowitz 1990).  For high precision 
measurements, Horowitz (1990) recommends that the annealing temperature accuracy 
should be within ±5%.
2.3.1.2.5 Dose Rate Dependence
LiF:Mg,Ti show no dose rate dependence at dose rates used for clinical treatment, 
however this has only been documented to within a level of accuracy of 5% (Kron 
1994).
2.3.1.2.6 Variation with Radiation Quality
The energy response of TL materials to X-rays depends on various factors including 
the effective atomic number, dopants and impurities, supralinearity differences 
between radiation qualities, attenuation within the material itself (particularly low 
energy X-rays can be absorbed within a large crystal), the read-out process, the size of 
the detector and the thermal history of the material (Kron 1994).
2.3.1.2.7 Accuracy and Precision
The accuracy of the readings depends ultimately on the reproducibility (precision) of 
the dosimeter and the standard dosimeter used to define its sensitivity.  Some groups 
have reported precision to below 0.5% for a single standard deviation, however a 
reasonable effort will allow a precision of around ±2% or better, as long as a 
correction is made for the individual dosimeter (Kron 1994).
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2.3.1.3 LiF:Mg,Ti Thermoluminescence Dosimetry in Brachytherapy
In 1995, Kirov, Williamson et al. (1995) used LiF:Mg,Ti TLDs along with diodes to 
measure dose-rate profiles and anisotropy function values of an Ir-192 HDR 
brachytherapy source.  The results were compared to Monte Carlo simulations and 
agreement was established to within 5% on average.
Anagnostopoulos, Baltas et al. (2003) reported on the use of LiF:Mg,Ti for dose 
verification of Ir-192 HDR prostate brachytherapy.  Their measurements were 
undertaken for five patients either receiving HDR monotherapy (four fractions of 9.5
Gy each) or HDR as a boost to external beam radiotherapy (three fractions of 7 Gy 
each).
A batch of 50 LiF TLD type-100 cylindrical rods – 6 mm long and 1 mm in diameter 
were used.  The pre-irradiation annealing cycle of one hour at 400°C followed by two
hours at 100°C was used, and the Harshaw Model 5500 Automated TLD Reader was 
used with a maximum acquisition temperature of 270°C and a constant heating rate of 
15°C s-1.
The TLDs were calibrated under a 6MV photon beam and each TLD was given an 
individual sensitivity factor.  
For the in vivo measurements, the TLDs were inserted into a thin plastic needle which 
was then placed inside a plastic brachytherapy needle that had been inserted into the 
patient’s prostate.
The mean differences between the measured dose and the dose calculated by the 
treatment planning system (PLATO BPS v. 14.2.2 (Nucletron B.V. The Netherlands), 
which incorporates a full TG-43 dose calculation algorithm) varied up to 
approximately 7%.  In view of the uncertainties discussed in the report, the authors 
were satisfied that the differences were acceptable, and the dose was reproducible 
over all the fractions administered to each patient.
Another study using LiF:Mg,Ti TLDs was conducted by Brezovich, Duan et al. 
(2000).  This group packaged the same TLD type-100 rods into a linear array 
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configuration of typically 20 rods inserted into a closed-ended brachytherapy catheter.  
The TLD-loaded catheter was sterilised using ethylene oxide gas (no effect was noted 
with sterile/non-sterile measurements).  This catheter was then inserted to the tip of 
the urinary catheter for the duration of an HDR prostate treatment, and the measured 
doses were compared to the treatment plan.  
The results of this study showed good agreement between measured and computed 
urethral doses.  The measured doses were typically lower than computed doses, and 
all measurements fell within the range of experimental error.
The authors noted some areas of the study that could be improved if the method was
to be used on a regular basis.  These areas include improvement of positioning and 
localisation of the TLD rods, improvement of spatial resolution, and the potential for 
the TLDs to be available commercially precalibrated and sterilised, saving significant 
time in the process.
Williamson and Rivard (2005) discuss energy response for TLD-100 based on the 
literature.  They show that the relative energy response of TLD-100 at mean Ir-192 
energies of 375 keV (Khan, 2003) is approximately 1.04 at distances around one cm 
from a point source compared to higher energy photon beams (Cs-137, mean energy 
662 keV (Khan, 2003)).  This response is reported to be closer to 1.00 at 10 cm from 
the point source (Williamson and Rivard, 2005).  The same authors suggest that LiF 
TLDs (TLD-100) have become the detector offering the best compromise between 
small size, sensitivity, energy response and ease of positioning for brachytherapy, and 
is currently accepted as the experimental gold-standard for measurement of absolute 
dose rates in brachytherapy.
The in-phantom response of LiF:Mg,Ti (TLD-100) using an Ir-192 source was 
assessed by Pradhan and Quast (2000).  Using 1 mm x 1 mm x 6 mm TLD rods and 
standard annealing and processing procedures, the authors found that the expected 
uncertainty amounted to less than 3% when compared to a PTW 0.3 cm3 ionisation 
chamber.
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More recently, Das, Toye et al. (2007) used LiF:Mg,Ti TLDs on 48 patients to verify 
dose delivered in the urethra and rectum during HDR brachytherapy.  The TLDs used 
were 1 mm diameter and 6 mm length.  The TL detectors were individually calibrated 
under a 6 MV beam from a linear accelerator to a dose of 0.5 Gy.  This group found 
that the TLD results matched well with the planning data, with the average difference 
being 0.1 Gy to the urethra and 0.17 Gy to the rectum.  In their discussion, the authors 
state that “it is unlikely that the calibration using a 6 MV X-ray beam from a linear 
accelerator is introducing an error exceeding 3%”.  However, they report a significant 
supralinearity effect, suggesting that future studies would require control TLDs to be 
irradiated to high doses simultaneously with the patient dosimetry.
The same group, Toye, Das et al. (2008) in an accepted manuscript (in press at the 
time of writing) extended the work reported in their previous publication (Das, Toye 
et al. 2007) by analysing rectal doses.  By incorporating a shift correction, the results 
improved compared with those previously reported.  This study adds to the evidence 
that LiF:Mg,Ti is suitable for in vivo dosimetry in prostate HDR brachytherapy.
2.3.2 Other In vivo Dosimetry Options for Brachytherapy
Various studies involving materials other than LiF:Mg,Ti TLDs have been published. 
Hood, Duggan et al. (2002) investigated the use of LiF;Mg,Cu,P TLDs for 
brachytherapy dosimetry.  This was only a relative study, but the TLDs showed good 
relative agreement with the treatment planning system (ADAC Pinnacle), however 
limitations in the TLD energy correction did not allow for absolute dose comparisons.
Duggan, Bucci et al. (2004) also suggested the use of LiF:Mg,Cu,P TLD material for 
prostate HDR brachytherapy in vivo dosimetry measurements.  The reasons for using 
this material are listed as the more uniform response to different photon energies 
compared with LiF:Mg,Ti, improved sensitivity allowing for better precision and 
improved spatial accuracy using miniature TLDs.  No studies have been published 
showing results using this material in brachytherapy.
Pai, Reinstein et al. (1998) used radiochromic film with a vaginal cylinder 
brachytherapy treatment geometry.  The film was placed on the outside of the 
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cylinder, and covered with a rubber sleeve prior to insertion.  The variation between 
calculated and measured dose was ±10% and the dose could not be read until the 
applicator was removed.  This makes it less accurate than other reported methods and 
feasibility for use with prostate brachytherapy is limited.
Alecu and Alecu (1999) used silicon diode detectors to measure the in vivo rectal dose 
during cervical HDR treatments.  The same concept is applicable to prostate 
treatments as the diode was inserted into a hollow rectal marker.  Phantom 
measurements gave measurement values within 5% of calculated values.  For in vivo
measurements, the results were not as satisfying, with differences up to 15% between 
measured and calculated doses.
Kipouros, Papagiannis et al. (2003) published a study using a radiosensitive polymer 
gel and MRI to obtain a 3D dose verification for HDR prostate monotherapy.  This 
study was not done in vivo, but was done in a phantom where a plan was used to treat 
the homogeneous gel.  This provided a simulation of a patient’s treatment, and was a 
good comparison between the planning system and real dose measurements; however 
it is not feasible to use this as a quality assurance procedure for every patient due to 
the time involved in reproducing the individual patient setup in the gel.
Cygler, Saoudi et al. (2006) performed a feasibility study using micro-MOSFETs 
(Metal Oxide Semiconductor Field Effect Transistors) for in vivo dosimetry of 
permanent brachytherapy seed implants.  These were used to measure dose rate in the 
urethra in real time.  The major advantage of this for permanent seed brachytherapy is 
that extra seeds may be added if it is deemed that the urethral dose is lower than 
expected and therefore prostate coverage compromised.
Lambert, McKenzie et al. (2006) developed a scintillation dosimeter thin enough to 
be inserted into the urethral catheter to measure the dose to the urethra in an HDR
prostate brachytherapy treatment.  The scintillation detector was attached to an optical 
fibre and this design was aimed to allow real-time dosimetry in brachytherapy.  It was
designed with a small detector volume, allowing high spatial resolution required for 
measurement in the steep dose gradients involved in HDR brachytherapy.  Readings 
from this dosimeter were achieved to within 3% of predicted values.
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Lambert, Nakano et al. (2007) – the same Group that developed the scintillation 
dosimeter above (Lambert, McKenzie et al. 2006), published a comparison of various 
in vivo dosimeters for HDR brachytherapy.  They included a diamond detector, 
MOSFET, TLD and scintillation detector (BrachyFOD).  The TLDs used in this study 
were LiF:Mg,Ti with dimensions 3 x 3 x 0.9 mm3.  They reported that these TLDs 
provided limited use in brachytherapy due to their potential for large errors.  This was 
attributed partly to the depth dependent sensitivity of the LiF chips, as well as small 
differences in absorbed dose in solid water compared with liquid water for low energy 
photons.
2.4 Summary
Little work has been published on prostate imaging specifically for HDR purposes 
where both prostate delineation and needle location are important.  These 
requirements lend themselves to establishing a hybrid of different imaging techniques 
to utilise the best properties of multiple imaging techniques.  
The current procedure used at St George Hospital (CT imaging only) may benefit 
from the introduction of MR imaging into the planning process, particularly with 
regard to dosimetry implications.  The literature overwhelmingly indicates that CT 
imaging over-estimates the prostate volume and that MR imaging gives a more 
accurate representation of the prostate location and size.  Dosimetrically, this would 
indicate that a larger volume than necessary receives a high dose of radiation and 
therefore, surrounding critical structures may be receiving more dose than is 
necessary for tumour control.
In vivo dosimetry in HDR brachytherapy using LiF:Mg,Ti TLDs has been established 
through the work of a range of investigators as outlined in the literature review.  All of 
these published investigations used in vivo measurements to determine suitability.  
The aim of this work is to utilise this suitability to improve the HDR process at St 
George Hospital and to take the work of others back a step in an attempt to make the 
implementation of the TLD system more accurate.  
This involved the use of a phantom under strict conditions to determine the accuracy 
and precision of the TLDs and to determine if sufficient accuracy can be achieved by 
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using a linear accelerator to expose control TLDs.  This would simplify the in vivo
measurements by introducing a conversion factor to account for the differences in the 
radiation qualities used for the patient measurements and the controls, and provide 
greater confidence in the treatment delivery.
The main advantage of LiF:Mg,Ti TLD rods and the reason for choosing these over 
other available in vivo dosimeters was the cost and their well-established properties.  
LiF:Mg,Ti TLDs are also used at St George Hospital for external beam in vivo dose 
measurements in their chip form, as they are in many radiotherapy treatment centres.  
The annealing and readout process for this material is well documented and in regular 
use.  If these TLDs were to be suitable, it would allow a smooth integration into 
clinical use without the introduction of more expensive equipment.
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Chapter 3: A comparison of computed tomography (CT) and 
magnetic resonance imaging (MRI) for high dose rate (HDR) and 
pulsed dose rate (PDR) prostate brachytherapy.
Due to the advantages of MR over CT for prostate imaging as outlined in Chapter 2, it 
may be expected that planning on MR images would improve brachytherapy 
treatment in terms of both accuracy and consistency.  The aim of this study was to 
determine whether this benefit could be confirmed quantitatively by an analysis of 
doses to the target volume and surrounding critical structures.  The potential for 
improved consistency of target volume delineation was considered by evaluating 
intra- and inter-observer variation.
3.1 Materials
This section will outline the materials and equipment used to obtain data for the 
comparison.  It will include details on the items used for the implant and imaging 
relevant to this project.  Anaesthetic equipment and general surgical equipment will 
not be discussed.
3.1.1 Implant Equipment
Various specialised items were used for each HDR brachytherapy implant.  These 
items were:
3.1.1.1 Ultrasound unit 
A Falcon Ultrasound Scanner Type 2101 (B-K Medical, Denmark) as shown in Figure 
3.1 was used in the operating theatre with a Bi-plane Transducer Type 8658 (B-K 
Medical, Denmark) for trans-rectal visualisation of the prostate during the implant 
procedure. 
37
Figure 3.1 Falcon Ultrasound Scanner (B-K Medical, Denmark)
3.1.1.2 Stepper/Stabiliser
A Barzell Microtouch system with stabiliser and brachystepper (Barzell-Whitmore 
Maroon Bells Inc, Florida) was used to step the ultrasound transducer through the 
rectum to obtain accurate prostate dimensions and images.  It is shown assembled 
with the ultrasound probe in Figure 3.2 below.
      
Figure 3.2 Barzell Microtouch system (Barzell-Whitmore Maroon Bells Inc, 
Florida) with ultrasound probe attached, and in use for HDR prostate 
brachytherapy implant
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3.1.1.3 Brachytherapy Grid
A Perspex grid was developed in-house to allow MRI scans to be taken, avoiding the 
risk of ferromagnetic materials being taken into the MRI suite.  The grid is shown in 
Figure 3.3 below.  The grid was sterilised with Ethylene Oxide between patients.  
Autoclaving caused the Perspex to expand, closing up the holes such that the needles 
were unable to pass through.  The grid was modelled on the standard grid used for St 
George Hospital HDR prostate brachytherapy patients – the HDR Contour Template 
from Mick Radio-Nuclear Instruments, Inc (New York).
Figure 3.3 Perspex prostate brachytherapy template, manufactured at St George 
Hospital based on HDR Contour Template (Mick Radio-Nuclear Instruments 
Inc, New York).
3.1.1.4 Marker Seeds
ACCULOC® soft tissue gold marker seeds (CMS alphatech, Sydney Australia) were 
used in all patients for this study.  Two seeds were placed at the base of the prostate, 
and one at the apex under ultrasound guidance.  
3.1.1.5 Pathfinder Needles
Pathfinder needles from Mick Radio-Nuclear Instruments Inc (New York) were used 
to pierce the skin and create the tracks through the prostate prior to the insertion of the 
brachytherapy needles.
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3.1.1.6 Brachytherapy Needles
Six French (French catheter scale – equivalent to 2 mm outer diameter), 240 mm 
length Oncosmart Proguide sharp needles supplied by Nucletron Pty Ltd (Australia)
were used for all patients in this study.  They are shown in Figure 3.4.  A minimum of 
18 needles and a maximum of 22 needles were used in each patient as determined 
necessary by the Radiation Oncologist to obtain adequate treatment options for 
coverage of the prostate. 
3.1.1.7 CT Markers
Specialised CT markers (Nucletron Pty Ltd, Australia) were used for the simulation 
and CT scans.  These markers are made of copper and have a radio-lucent section 
between the tip and the remainder of the marker as shown in Figure 3.4.  This design 
allows easy determination of the first dwell position possible within each needle on 
the CT scan.
Figure 3.4 Oncosmart Proguide sharp needles and CT markers (Nucletron, 
Australia).
3.1.1.8 Rectal Marker
All patients had a Shadowform® 10 cm rectal marker with T-bar handle (IZI Medical 
Products Inc, Baltimore) inserted into the rectum to assist with visualisation on the CT 
images.  The rectal marker is shown in Figure 3.5.
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Figure 3.5 Shadowform® rectal marker (IZI Medical Products Inc, Baltimore).
3.1.2 Simulator
All patients had an x-ray film of their implant taken on a Ximatron Simulator (Varian 
Medical Systems, Australia), pictured in Figure 3.6.
Figure 3.6 Ximatron Simulator (Varian Medical Systems, Australia)
41
3.1.3 CT Scanner
All patients for this study were scanned using a single slice Toshiba Xpress SX 
Computed Tomography Scanner (Toshiba Australia Pty Ltd, Australia).  Helical scans 
were taken as per the protocols developed for brachytherapy at St George Hospital.  
The parameters used are listed in Table 3.1 below.
Table 3.1 CT Scanning Parameters
Parameter Value
Field of View 240 mm2
Slice Thickness 5 mm
Slice Spacing 5 mm
Gantry Tilt 0°
kVp 120
mA 300
3.1.4 MRI Scanner
All patients for this study were scanned using a Philips Intera 1.5 Magnetic 
Resonance Imaging unit.  Software version 11.1.4.3 was used.  Axial T1 and T2 scans 
were taken with parameters listed in Table 3.2 below.
Table 3.2 MRI Scanning Parameters
Parameter Axial T1 Axial T2
Field of View 240 mm2 240 mm2
Number of slices 40 40
Slice Thickness 5 mm 5 mm
Slice Spacing 0 mm* 0 mm*
TR (Repetition Time) 530 3302
TE (Echo Time) 10 80
Matrix size 256 x 320 256 x 512
NSA (Number of Signal 
Averages)
3 2
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* Slice spacing of 0 mm in Table 3.2 is equivalent to slice spacing of 5 mm listed in 
Table 3.1 for the CT scans.  This means that the slices are contiguous (one slice 
commences immediately after the previous slice).
3.1.5 Planning Systems
3.1.5.1 Anatomy Modelling
The planning system used for fusion of CT and MR images as well as for the 
delineation of the organs of interest was the Oncentra Masterplan system (Nucletron
Pty Ltd, Australia).  Version 1.5 Service Pack 1 was used (Software v1.5.1.11, 
Documentation v1.5.1.5).  The anatomy modelling component of the software was 
used.  A Wacom tablet monitor and stylus supplied by Nucletron Pty Ltd Australia
was used for the voluming of all structures.
3.1.5.2 Brachytherapy Planning
The planning system used for the brachytherapy treatment including implant 
reconstruction and dose calculations was the Plato Brachytherapy Planning System 
(BPS) Version 14.3.5.
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3.2 Methods
3.2.1 Patient details
A total of nine HDR prostate brachytherapy patients were scanned with both CT and 
MRI.  One patient (Patient 7) had a hip replacement, creating severe artefact in the CT 
images and making the MR images less sharp.  One patient’s data was difficult to fuse 
in Oncentra Masterplan as it appears that the rectal marker was displaced between the 
two separate scans, causing some distortion in the anatomy (Patient 6).  Patient data 
was anonymised prior to any delineation of organs taking place.  
3.2.2 Implant procedure
The implant procedure was complex and required a multi-disciplinary team including 
Anaesthetists, theatre staff, a Radiation Oncologist, a Urologist and a Radiation 
Therapist or Physicist.  A brief summary of the procedure will be provided here.
The patients were required to perform a bowel preparation involving the use of Fleet 
Enemas prior to the procedure.  The patient was placed under a general anaesthetic in 
the operating theatre and placed into the lithotomy position.
The procedure commenced with the insertion of the rectal ultrasound probe.  The 
probe was attached to the stepper unit, allowing accurate visualisation of 
superior/inferior distances through the rectum.  The prostate size and position was 
assessed to ensure the procedure was going to be possible. The main reason for 
abortion of the procedure is pubic arch interference – where the pubic bone is in the 
path of the brachytherapy needles and coverage of the disease would not be possible.  
The brachytherapy template was stitched onto the perineum.
Three gold marker seeds were inserted via ultrasound guidance through the 
brachytherapy template and into the prostate.  Two seeds were placed at the base of 
the prostate and one seed at the apex.  These seeds were used for localisation of the 
prostate and quality assurance purposes.
Pathfinder needles were used initially to pierce the skin through the brachytherapy 
template and to create a track through the prostate as viewed on the ultrasound unit.  
Brachytherapy needles were inserted through these tracks into the prostate.  The grid 
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locations of each needle were noted.  Care was taken to avoid piercing the urethra and 
the rectal wall. The needles were all pushed beyond the end of the prostate to ensure 
complete coverage.  For this project, 18 to 22 needles were inserted in each patient, as 
decided by the Radiation Oncologist to ensure adequate coverage of the entire 
prostate.  Fluoroscopy was also used in conjunction with the ultrasound to ensure the 
needles were placed in adequate locations.  The length of each needle protruding from 
the end of the grid was measured and adjusted so that all needles were at an 
equivalent depth.
At the end of the procedure, a cystoscopy was performed to ensure the urethra had not 
been damaged by the needles, and the anterior rectal wall was palpated to ensure there 
were no needles passing through it.
A 3-way Foley catheter was inserted to allow for irrigation of the bladder (the needles 
often pass all the way into the bladder causing bleeding and therefore irrigation is 
necessary to avoid blood clots) and a rectal marker was inserted for improved 
visualisation of the rectum on the CT scans.  The patients were given a PCA (Patient 
Controlled Analgesia) allowing self-administration of morphine as required.  A 
Perspex protective cone was placed over the needles and attached to the 
brachytherapy grid.  The purpose of this cone was to prevent the needles digging into 
the patient’s bed.
The patients were sent to Recovery to be roused from the general anaesthetic.
3.2.3 Imaging procedures
There were three components to the imaging for these patients.  They will be 
presented here in the order in which they were completed.  
3.2.3.1 Simulation
The patients were taken to the Radiotherapy Simulator where a reference x-ray film 
was taken.  The film was taken with CT markers placed in two lateral needles in a 
mid-prostate plane, as well as a 10 cm magnification marker in another needle in the 
same plane.  The film was taken in the anterior to posterior direction.  Adjustments to 
the needle positions were made if there was inadequate coverage of the prostate based 
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on the CT marker position compared with the gold marker seed location, both clearly 
visible on the film.  Usually this involved inserting the needles further through the 
prostate.  Again, all needles were adjusted so that equal lengths protruded from the 
brachytherapy grid.  The final film taken at the Simulator was then the reference film, 
to which all subsequent films would be compared.  Mobile X-ray films were taken 
prior to each fraction and the position of the implant with respect to the gold marker 
seeds was compared to the reference film and adjusted if necessary.
3.2.3.2 CT Scan Procedure
Helical scans were taken for this project.  The CT gantry was set to 0.0°, slice 
thickness set to 5 mm and slice spacing also set to 5 mm to give contiguous images.  
This thickness and spacing was selected to correspond with the brachytherapy source 
stepping positions of 5 mm as defined in Plato BPS.  The afterloader has the ability to 
step the source in 2.5 mm increments, and a smaller slice thickness and spacing would 
give more accuracy in defining the extent of the prostate in the superior to inferior 
direction and the precise location of the first dwell position, however it would 
increase the time involved in organ delineation and planning the patient’s treatment.  
The decisions on the settings used were based on a balance between accuracy and 
time for organ delineation and planning.
Due to the movement of the patient from simulator couch to bed, and from bed to CT 
couch, the needle positions were verified prior to scanning to ensure they had not 
shifted with respect to the brachytherapy grid.  The patient was set up on the CT 
couch as closely as possible to the proposed treatment position.  
CT markers were placed into all the needles prior to scanning.  A scout image was 
taken and the region of interest selected, ensuring the CT scan covered the region 
from the brachytherapy grid to several slices above the tips of the needles.  A field of 
view of 240 mm2 was used to zoom in on the prostate, as Plato BPS is limited in its 
ability to zoom in on the images.
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3.2.3.3 MRI Scan Procedure
The MRI settings were selected to match the CT settings used as a part of the 
brachytherapy imaging protocols at St George Hospital.  Two series of images were 
taken as outlined in Table 3.2 above.  The patient position was matched as closely as 
possible to the CT position.  Needle positions were verified to within the tolerance 
level of ±1 mm by measuring the length of needle protruding from the brachytherapy 
grid as for the CT scan procedure.  The time period between CT and MRI scans 
ranged between approximately thirty and ninety minutes.
3.2.4 Planning procedure
As this was a retrospective study on the imaging of prostate brachytherapy cases, the 
planning procedure described here was that used in this study only and differs from 
current clinical treatments.
3.2.4.1 Image Fusion
All CT and MR images were imported into Oncentra Masterplan and anonymised.  
Fusion of the CT images with the Axial T1 MR images was performed using the 
Landmark Fusion method.  Various points along each needle around the region of the 
prostate (based on the implanted marker seeds) were correlated between the two 
image sets providing a good match between the images of needle position.  This 
automatically created a fusion between the CT and Axial T2 MR images.  This 
method was chosen due to the lack of external body contour on the images, as well as 
the movement of the implant with respect to other anatomical landmarks in moving 
the patient from the CT couch to MRI.  It was assumed that the prostate did not move 
with respect to the needles piercing it.  If there was swelling of the prostate between 
the scanning procedures, the needles would have shifted with the prostate, so any 
error in fusion caused by swelling would be minimised.  If the prostate shifted parallel 
to the needles piercing it, the fusion using this method could be in error.  To account 
for this, the gold marker seeds were also used as Landmark fusion points.
3.2.4.2 Organ Delineation
Organ volumes were delineated by two Radiation Oncologists on two sets of images 
for each patient.  The first was the CT alone, with a hard copy of the ultrasound 
printouts from theatre available for reference (CT plan 1 and CT plan 2 for Oncologist 
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1 and 2 respectively), and the second was the CT/MR fused image set (MR plan 1 and 
MR plan 2 for Oncologist 1 and 2 respectively).  It was found that the prostate was 
more clearly defined on the Axial T2 fusion than the Axial T1 fusion for all patients, 
so this was the MRI set used for delineating the organs.  
As only two Oncologists delineated the organs on all data sets, the data presented here 
is expected to potentially show some trends, however a larger cohort of Oncologists 
would be necessary to improve statistical rigour of the results and provide conclusive 
evidence regarding the benefit of MRI in prostate brachytherapy.
A rectangular body contour was placed around each of the images as required for the 
Plato BPS dose calculations.  The marker seeds were delineated to assist in defining 
the base and apex of the prostate.  The anatomical structures delineated by the 
Oncologists were the prostate (target), urethra and rectum.  A peripheral zone was 
also added, following the shape of the target, but curving in a horseshoe shape around 
the urethra.  This technique is used routinely at St George Hospital to assist in 
obtaining a good initial plan using the IPSA (Inverse Planning Simulated Annealing) 
optimisation algorithm.
3.2.4.3 Treatment Planning
After the organ delineation was completed by the Oncologists, the images and 
structure sets were transferred to Plato BPS via a network connection.  Once imported 
into Plato BPS, the catheters (needles) used for the patient’s treatment were marked.  
A total of 18 catheters were marked for each patient.  Some patients had more than 18 
catheters implanted, however the Nucletron PDR afterloader available at St George 
Hospital only had capacity for 18 channels.  The additional needles were placed to 
allow greater choice as to which needles to use for treatment.  The decision on which 
needles to leave out of the plan was based on various factors including proximity to 
the urethra, proximity to other needles and location within the prostate based on the 
delineated organs on CT plan 1.  All plans generated for each individual patient used 
the same 18 needles.
Patient points were placed along the centre of the urethra, or the expected region of 
highest urethral dose on slices where the urethra was not within the prostate volume.  
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Patient points were also placed in the rectum at a distance of 5 mm from the anterior 
rectal wall as per the St George Hospital protocol.
The viewing axes were rotated to match the axes of the needles through the prostate, 
however the centre of the co-ordinate system was not adjusted from the default 
position allocated as the centre of the target volume by Plato.
IPSA was used to generate an initial reference plan on CT plan 1.  This data set was 
chosen as it represented the clinical situation at the time these patients were treated.  
A total dose of 650 cGy was prescribed and the class solution is listed below in Table 
3.3.  The same class solution was used for each patient.  
Table 3.3 St George IPSA Class Solution
Volume of 
interest
Margin 
(mm) 
dose 
control
Margin 
(mm) 
catheter 
activation
Organ 
type
Minimum 
surface 
dose 
weight
Minimum 
surface 
dose 
(cGy)
Maximum 
surface 
dose 
(cGy)
Maximum 
surface 
dose 
weight
Minimum 
volume 
dose 
weight
Minimum 
volume 
dose 
(cGy)
Maximum 
volume 
dose 
(cGy)
Maximum 
volume 
dose 
weight
Peripheral 
zone
0.0 5.0 Target 120 650.0 975.0 120 120 650.0 975.0 100
Rectum 0.0 0.0
Organ at
risk
0 0.0 455.0 50 0 0.0 455.0 50
Target 1.0 5.0
Reference 
target
100 650.0 975.0 100 100 650.0 975.0 30
Urethra 0.0 0.0
Organ at 
risk
100 650.0 715.0 120 100 650.0 715.0 120
After running the IPSA algorithm, the graphical optimisation method was used to 
obtain a plan appropriate for patient treatment with constraints as per the St George 
protocol shown in Table 3.4 below:
Table 3.4: St George protocol for dosimetric parameters to aim for when 
planning prostate HDR brachytherapy. (TROG 2003)
Dosimetric Parameter Constraint
Dose to urethra < 120% of prescribed target dose
Dose to rectum < 70% of prescribed target dose
D90 (Target) > 100% of prescribed target dose
V100 (Target) > 95%
V150 (Target) < 50%
V200 (Target) < 15%
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D90 represents the dose to 90% of the target volume and should be at least 100%.  V100
represents the percentage of the target volume receiving 100% of the prescribed dose.  
This should ideally be greater than 95%, however it may be reduced if the rectum is 
too close to the prostate to avoid rectal complications.  V150 and V200 represent the 
target volume receiving 150% and 200% of the prescribed dose respectively.  This is 
an indication of hot spots.  Hot spots are expected around each source; however large 
regions of high dose are not desirable.  
As a comparison, the dwell times planned on the reference data set (CT plan 1) were 
copied across to the other three data sets (CT plan 2, MR plan 1 and MR plan 2)
generating a total of four plans per patient.  As the patients were treated using the 
reference image set, the non-reference plans represent the dose delivered to the 
prostate and critical structures if these organs were incorrectly represented on the
reference CT plan and the alternative volume sets were correct.  The same 
prescription dose and treatment time were entered to place the same isodose pattern 
on all data sets.
Dose volume histograms (DVHs) were calculated for all plans and analysed to 
determine target volumes and differences in various dosimetric parameters as detailed 
in Section 3.2.5.  
3.2.5 Analysis procedure
3.2.5.1 Defining needle position
Defining the first dwell position within each needle is important for correct 
positioning and therefore accurate delivery of the brachytherapy treatment.  The CT 
images and MR images were visually inspected to determine the modality in which 
the needle tips were clearly defined.
3.2.5.2 Inter-observer variation
The variation in total volume, length, height and width of the prostate contours across 
the central planes was determined and the difference between image sets and 
Oncologists was analysed.  This variation was assessed for CT alone as well as for the 
CT/MR fused images to observe any benefit in terms of consistency when using MR
images in addition to CT.  The gold-standard which all data was compared to was 
50
chosen to be the average dimensions of the prostate from all four data sets (as outlined 
in section 3.2.4.2) for each patient.
To obtain the volume of the target, a DVH table was generated in Plato BPS for the 
target.  The DVH table was then used to determine the volume in cubic centimetres of 
the prostate.  
The DVH data was obtained from Plato BPS using a sample size of 60000 points.  
Lower dose limit was set to 0 and upper dose limit to 4.  These dose limits are 
multiples of the prescribed dose, so the upper dose limit of 4 means that the DVH data 
extended to 4 times the prescribed dose of 650 cGy = 2600 cGy.
The length, height and width were determined using the “Ruler” function in Plato 
BPS on the two-dimensional reconstructed images, along the axes of the target 
volume (Figure 3.7).  The error in measurement using this method was estimated to be 
±0.2 mm for the height and width, however the error in the length was greater due to 
the 5 mm slice thickness and spacing, and was therefore estimated as ±2.5 mm.  
Length was measured as the superior to inferior length (from apex to base), height 
was measured as the anterior to posterior distance and width was measured as the 
lateral (left to right) distance of the target volume.
Figure 3.7 Prostate dimensions
Length
Width
Height
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The location of the base and apex was assessed for each case and compared to the 
gold standard (average location from all four data sets).  This was to determine if one 
imaging modality showed greater consistency than the other in defining these superior 
and inferior levels of the prostate.
3.2.5.3 Intra-observer variation
For each individual Oncologist, the variation between CT alone and CT/MR fused 
images was analysed for the same parameters as listed above in Section 3.2.5.2 using 
the same methods.  The purpose of this was to determine the extent of difference in 
volumes by each individual Oncologist using the two different imaging modalities.
3.2.5.4 Target Dosimetry Analysis
The dwell times from the optimal treatment plan created on CT plan 1 were copied 
into each of the other data sets so that the same treatment plan was applied to all four 
organ volume sets for each patient.  The parameters analysed for comparison between 
each modality based on CT plan 1 were: D80, D90, D100, V80, V90, V100, V150 and V200, 
where Dx is the dose received by x% of the target volume, and Vy is the target volume 
receiving y% of the prescribed dose.  The complexity of creating an “average” set of 
volumes based on all Oncologists’ volumes was beyond the scope of this project.
An analysis of 200% regions outside of the target was completed to determine how 
much normal tissue was exposed to very high doses of radiation based on the contours 
from the different imaging modalities.  The extent of these regions was calculated 
from DVH data by determining the volume in cubic centimetres of the 200% dose 
regions inside the target, subtracted from the 200% regions inside the Body contour.  
The procedure was repeated for the 150% regions.
3.2.5.5 Critical Structure Dosimetry (Toxicity)
Maximum urethral and rectal doses at the patient points described in Section 3.2.4.3 
were compared for each of the four plans.  A further analysis of the doses to the 
urethra and rectum was considered by looking at the maximum dose to 2 cc, 1 cc and 
the maximum point dose to the organs (dose to 0.01 cc), all based on DVH data.  
These parameters were not used in the analysis of these patients’ treatment plans, 
however they have become more commonly used parameters at St George Hospital 
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recently.  They were obtained from DVH data.  The upper dose limit was set to 2 
(1300 cGy) for the rectum and 3 (1950 cGy) for the urethra (refer to Section 3.2.5.2
for the definition of upper dose limit).
Standard deviations were used throughout the analysis procedure to define the errors 
involved in the comparison of the four data sets analysed.  All standard deviations in 
this project were calculated using equation 3.1 (Kirkup 1994):
)1(
)( 2


n
xx Equation 3.1
Where x is the individual result, x is the mean result, and n is the sample number.
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3.3 Results and Discussion
3.3.1 Defining needle position
The needles used in this study were made of a plastic material, however a copper CT 
marker (Section 3.1.1.7) was inserted into each needle for the CT scan.  This marker 
clearly showed the needle positions on the CT scan, including the location of the first 
possible dwell position for the Ir-192 source near the tip of the needle.  No markers 
were placed in the needles for the MR scan as there are no MRI markers 
commercially available, and the needles appeared as dark spots on the image.  There 
is no clear method to distinguish between the needle and an empty needle track.  
Examples of each image are shown below in Figure 3.8.  The CT image on the left 
clearly defines the CT markers (white spots).  The prostate is much clearer on the MR 
image on the right, however there is no difference in the MR image between needles 
and empty needle tracks making it difficult to locate the tips of the needles accurately. 
Therefore, for accuracy, it is important to include the CT data in the planning process.  
If using MR data to define the prostate, it should be fused with the CT data to ensure 
the needle locations are accurately defined in the brachytherapy planning system.
Figure 3.8 CT (left) and MR (right) images of the prostate brachytherapy 
implant.  
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3.3.2 Target volume and dimension variations
Figure 3.9 shows the average target volume, length, width and height for all four data 
sets, averaged for all nine patients.  This graph demonstrates both inter- and intra-
observer variation in the target volume and dimensions.  CT plans are indicated by the 
pale colours and MR plans are indicated by the dotted darker colours.  The error bars
here represent one standard deviation from the average value over nine patients, and 
as such represent the variation in prostate sizes between the nine patients.  The sizes 
of the error bars in this plot do not indicate clearly that one data set consistently gave
smaller volumes or dimensions than another; however there were notable trends in the 
average data.  On average, the MR data sets gave smaller target volumes than CT data 
sets, and particularly the length and width of the target were on average smaller on the 
MR data sets.
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Figure 3.9 Average target dimensions for nine patients.
From the data in Figure 3.9, the trend on the average data showed that the average 
volume of the prostate when delineated with MR imaging was smaller than when 
delineated with CT imaging.  However, the consistency between Oncologists was 
slightly worse with MR imaging.  This may be due to a learning curve effect as the 
Oncologists were not familiar with defining the prostate for brachytherapy using MR 
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imaging.  As Figure 3.9 is an average of all the data, figures 3.10 – 3.13 have been 
presented below to show the results for each patient.
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Figure 3.10 Target volume for each patient
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Figure 3.11 Target length (sup/inf) for each patient
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Figure 3.12 Target height (ant/post) for each patient
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Figure 3.13 Target width (left/right) for each patient
From Figure 3.10 it can be seen that there was no significant effect of prostate size on 
the variability of results.  The spread of the data was reasonably consistent for all 
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patients, with the greatest variability observed in Patient 3.  There were no obvious 
irregularities in Patient 3 that would cause this variability compared with other 
patients.
The scales of the Y-axis in figures 3.11 – 3.13 are equivalent.  Therefore it can be 
seen that the length (superior to inferior length) of the prostate showed the most 
variability of the three dimensions examined, and was therefore the largest area of 
uncertainty in defining the target volume. 
As discussed in Section 3.2.1, Patient 7 had a hip replacement, and the CT data set 
had significant artefacts that may have interfered with accurate target delineation.  
However, as can be seen in Figures 3.10 to 3.13, the intra-observer and inter-observer 
differences were not significantly different to the other cases.  The MR imaging in this 
case did not provide a clear benefit to defining the target volume.
MR imaging did not consistently determine the length of the prostate to be shorter 
than it had been defined in the CT imaging, however Figure 3.14 and 3.15 show the 
variation in the definition of the base and apex position for each patient.  
These results do not show any significant improvement in defining the base or the 
apex of the prostate using MR imaging.  The deviations between the Oncologists are 
similar when the prostate is delineated with CT as when it is delineated with CT/MR 
fused images.
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Figure 3.14 Deviation of Base from Gold Standard 
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Figure 3.15 Deviation of Apex from Gold Standard
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3.3.2.1 Inter-observer variation
Table 3.5 shows the results of the prostate volumes and dimensions for each 
Oncologist for CT alone (CT plan 1 and CT plan 2) for all patients.  Table 3.6 shows 
the results of the prostate volumes and dimensions for each Oncologist for the CT/MR 
fused data sets (MR plan 1 and MR plan 2) for all patients.
Table 3.5 CT Prostate Volumes and Dimensions
Patient
Oncologist 1 Oncologist 2
Volume 
(cm3)
Length 
(mm)
Height 
(mm)
Width 
(mm)
Volume 
(cm3)
Length 
(mm)
Height 
(mm)
Width 
(mm)
1 40.67 46.1 37.3 40.4 54.42 56.4 36.5 41.1
2 44.52 50.7 34.0 43.4 57.67 55.6 36.6 43.0
3 51.53 46.2 36.6 48.2 67.23 46.0 39.2 50.9
4 39.42 53.0 31.6 37.2 33.12 36.9 30.0 38.3
5 47.9 51.1 33.5 45.1 49.98 45.1 32.7 43.9
6 33.76 39.6 29.0 39.3 23.77 31.3 28.5 35.5
7 34.03 51.1 28.5 35.0 24.22 41.3 27.4 27.7
8 39.21 45.9 30.6 44.4 28.8 41.1 26.6 39.7
9 79.94 60.7 40.1 51.1 74.1 55.7 42.2 49.7
Table 3.6 CT/MR Prostate Volumes and Dimensions
Patient
Oncologist 1 Oncologist 2
Volume 
(cm3)
Length 
(mm)
Height 
(mm)
Width 
(mm)
Volume 
(cm3)
Length 
(mm)
Height 
(mm)
Width 
(mm)
1 37.88 40.4 36.8 35.6 49.94 45.5 37.7 37.8
2 38.45 40.6 33.0 37.9 37.86 50.2 32.0 37.6
3 32.84 26.4 39.4 44.9 26.16 36.0 30.2 39.0
4 35.00 52.5 31.6 32.3 31.71 42.7 31.9 36.1
5 38.54 46.4 37.8 40.2 46.89 46.1 35.1 40.8
6 25.22 40.9 28.5 33.2 19.03 36.4 26.1 28.9
7 28.94 40.9 31.8 30.5 25.5 36.7 31.3 30.0
8 37.35 51.7 31.4 34.5 28.85 40.9 28.9 36.5
9 85.62 61.2 48.4 55.4 70.46 55.0 44.0 50.5
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The average and maximum deviations between the Oncologists is shown in Table 3.7
for both CT alone and CT/MR fused image sets.  This is directly based on the data in 
Table 3.5 and 3.6 above.
Table 3.7 Inter-observer Deviations between two Oncologists in Target Volume 
and Dimensions
Image 
Set
Average deviation over nine patients
Maximum deviation on a single 
patient
Volume 
(cm3)
Length 
(mm)
Height 
(mm)
Width 
(mm)
Volume 
(cm3)
Length 
(mm)
Height 
(mm)
Width 
(mm)
CT only 0.3 3.9 0.2 1.6 15.7 16.1 4.0 7.3
CT/MR 
Fusion
2.6 1.3 2.4 0.8 15.2 10.8 9.2 5.9
3.3.2.2 Intra-observer variation
Table 3.8 shows for each Oncologist, the difference between prostate volumes and 
dimensions, comparing the CT only image set to the CT/MR fused image sets.  A 
positive number indicates that the dimension of the prostate delineated on the CT 
images was larger than the prostate delineated on the MR images, a negative number 
the reverse.
Table 3.8 Intra-observer Variation in Target Volume and Dimensions –
Difference between CT and fused CT/MRI
Oncologist 1 Oncologist 2
Volume 
(cm3)
Length 
(mm)
Height 
(mm)
Width 
(mm)
Volume 
(cm3)
Length 
(mm)
Height 
(mm)
Width 
(mm)
Average 
Deviation
5.7 4.8 -1.9 4.4 8.5 2.2 0.3 3.6
Maximum 
Deviation
18.7 19.8 8.3 9.9 41.07 10.9 9.0 11.9
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For both Oncologists, the maximum deviation in overall prostate volume occurred in 
the same patient (Patient 3).  The MR volume was smaller than the CT volume in all 
except three out of 18 data sets (one patient for Oncologist 1 and two patients for 
Oncologist 2 – all on different patients).
3.3.3 Target Dosimetry
The dose volume histograms created in Plato BPS were analysed and the results are 
presented below.  Figure 3.16 is a sample DVH plot for Patient 1.  The prescription 
dose was 650 cGy.  The reference plan (CT plan 1) is represented as the pale blue 
curve, which shows the best target coverage of the four plans.  This is expected as the 
plan was optimised for this target shape and critical structure positions.
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Figure 3.16 Normalised Target Dose Volume Histogram for Patient 1.
The typical target dosimetric parameters analysed at St George Hospital prior to 
patient treatment as discussed in Section 3.2.5.4 are presented in their average forms 
in Figures 3.17 and 3.18 below.  Error bars represent the maximum range of the data 
for the nine patients, and not the standard deviations.
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Figure 3.17 Target dosimetry data – D80, D90 and D100 (average over all nine 
patients).  Error bars represent maximum range of the data.
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Figure 3.18 Target dosimetry data – V80, V90, V100, V150 and V200 (average over all 
nine patients).  Error bars represent maximum range of the data.
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As the treatment plan for each patient was created based on the structures defined by 
Oncologist 1 on the CT data set (CT plan 1), the parameters were optimised for these 
organ delineations.  
If it was assumed that MR gave better target definition than CT based on the evidence 
presented in Sections 2.2.3.2 and 2.2.4, it could be concluded that the target volume 
was not being covered with as much radiation as intended.  Some parts of the target 
were receiving significantly less than 100% of the prescribed dose as seen from the 
V100 parameter in Figure 3.18 (dotted bars representing the CT/MR fused data sets).
Dosimetry parameters D90, V100, V150 and V200 used for determining plan suitability 
prior to treatment are separated out for each patient in Figures 3.19 – 3.22 below.  
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Figure 3.19 D90 (Dose received by 90% of the target volume)
The largest variation in D90 occurs in most patients between the plans placed on CT 
images (pale blue and pale orange squares).  According to the Oncologist 2 CT data, 
patients 1 – 4 are all receiving insufficient dose (D90 < 100%).  Five out of the nine 
patients are receiving insufficient dose according to the Oncologist 2 CT/MR fused 
data, and two of the patients are receiving insufficient dose according to the 
Oncologist 1 CT/MR fused data.
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Figure 3.20 V100 (Target volume receiving 100% of the prescribed dose)
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Figure 3.21 V150 (Target volume receiving 150% of the prescribed dose)
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Figure 3.22 V200 (Target volume receiving 200% of the prescribed dose)
From Figures 3.21 and 3.22, it can be seen that there were generally less hotspots 
within the target volume when it was delineated using CT/MR fusion.  Overall, the 
entire radiation dose to the prostate appeared to be less according to this DVH data.  
As the total dwell times are the same in all cases, there must be significant dose 
outside the target volumes.  Some dose is expected outside the target volume as the 
photon spectrum of Ir-192 drops off exponentially.  As the needles are spaced apart, 
there will be curves in the isodose distribution so it is inevitable that some regions 
outside the target will receive 100% or more of the dose to ensure as much coverage 
of the target with 100% as possible.  
As the regions outside the target are considered normal tissue, hot spots in these 
regions should be avoided.  Figure 3.23 represents the extent of the 200% hotspots 
(regions receiving at least 200% of the prescribed dose) outside of the target volume.  
Figure 3.24 is the same plot for the 150% regions.  In most cases, there are more 
200% hotspots outside the target for the CT/MR fused data sets than for the CT only 
data sets, which correlates with the result that MR imaging gives a smaller target 
volume than CT imaging.  In terms of clinical effects, this means that more normal 
tissue is being exposed to high doses of radiation than is expected.  A similar trend is 
observed with the V150.
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Figure 3.23 V200 (tissue volume receiving 200% of the prescribed dose) outside 
the target volume
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Figure 3.24 V150 (tissue volume receiving 150% of the prescribed dose) outside 
the target volume
It has been reported that CT typically overestimates the prostate volume (Dubois, 
Prestidge et al. 1998; Crook, Milosevic et al. 2002; Polo, Cattani et al. 2004; Solhjem, 
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Davis et al. 2004; Carey 2005; Miquel, Rhode et al. 2006), however this project 
shows that this extra margin inherent in CT delineation does not always encompass 
the entire prostate as determined by MR.  There were some regions outside the 
prostate as defined by MR imaging that received extra dose, however there were 
regions inside the prostate that did not receive the full treatment dose.  This initial 
investigation would suggest that CT does not always overestimate the prostate 
dimensions in all regions, thus the need to move to MR imaging may be greater than 
anticipated.
3.3.4 Critical Structure Dosimetry (Toxicity)
The maximum doses to the patient points described in Section 3.2.4.3 are displayed in 
Figure 3.25 below for each patient.  All points above the 100% line are urethral dose 
points and the points below the 100% line are rectal dose points.
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Figure 3.25 Urethra and Rectum Dose Points
From this plot there is no clear indication that the dose to the critical structures is less 
when defined with one imaging modality over the other.  However it does show that 
there is very little variation in the maximum dose to the urethra from both intra-
observer and inter-observer comparisons.  If the reference clinical plan was generated 
based on the CT/MR fused images, the doses to the critical structures would be 
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different.  The major limitation of this analysis is that the reference plan (CT plan 1) 
was applied directly to the other data sets, and not optimised for each data set 
individually.
There is more deviation in the rectal position with respect to the implant when 
compared with the urethral deviation.  In most cases, the MR images show the 
anterior wall of the rectum to be further away from the prostate than in the CT scan.  
This may be affected by rectal movement between the time of the CT scan and the 
MR scan.  This does not affect the urethra to the same extent as the urethra passes 
through the prostate and will tend to shift with the prostate and hence with the 
implant.
As the point doses are not fully representative of the dose received by the organs, 
DVH data was also analysed.  Figure 3.26 shows the average dose received by 2 cc, 1
cc and a single point in the rectum and urethra based on the plan generated on the 
Oncologist 1 CT data sets.  The dose received was on average, lower when the critical 
structures were delineated with the assistance of MR imaging.  The error bars 
represent one standard deviation from the mean.
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
160.00
180.00
200.00
R
E
C
T
U
M
 D
2
cc
R
E
C
T
U
M
 D
1
cc
R
E
C
T
U
M
 M
a
x
U
R
E
T
H
R
A
D
2
cc
U
R
E
T
H
R
A
D
1
cc
U
R
E
T
H
R
A
 M
a
x
Dosimetry Parameter
%
 o
f 
p
re
s
c
ri
p
ti
o
n
 d
o
s
e
ONCOLOGIST 1 CT
ONCOLOGIST 2 CT
ONCOLOGIST 1 CT/MR
ONCOLOGIST 2 CT/MR
Figure 3.26 Critical structure DVH data (average for nine patients)
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This result would allow for an increase in target dose whilst maintaining critical 
structure doses at acceptable levels, assuming that the MR imaging gave a more 
accurate depiction of the structure locations at the time of treatment.  The results for 
the individual patients for the rectum are displayed in Figures 3.27 – 3.29.  The same 
trend can be observed as in Figure 3.25 with the fused images in most cases showing 
less dose to the rectum than that from the CT imaging alone.
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Figure 3.27 Dose to 2 cc of the rectum
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Figure 3.28 Dose to 1 cc of the rectum
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Figure 3.29 Maximum dose to the rectum (dose to 0.01 cc)
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3.4 Conclusions
The results show that the volume of the prostate is significantly smaller when 
delineated on MR images compared with CT images.  Therefore, if it were assumed
that MR imaging still provided a more accurate, if not more consistent prostate 
delineation than CT imaging (Dubois, Prestidge et al. 1998), it may have a place in 
prostate brachytherapy to reduce the dose to normal tissue surrounding the prostate 
and obtaining better coverage of the smaller target volume, without compromising the 
critical structures.
The move to incorporating MR imaging would eliminate not only the overestimation 
of prostate volumes, but also any incorrect definition of prostatic tissue (areas of 
prostatic tissue not encompassed by the CT volumes).
Based on this study, there is no clear benefit in the use of MR for imaging the prostate 
in HDR or PDR brachytherapy in terms of achieving more consistent organ 
delineation between Oncologists.  Data for this study has only been collected from 
two Radiation Oncologists.  Therefore the data presented here is limited and a larger 
cohort of Oncologists would provide more conclusive results.  Due to time 
constraints, it was not possible to obtain data from more than two Oncologists.  This 
is a potential area for further work.
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Chapter 4: The use of LiF:Mg,Ti TLDs for in vivo prostate 
brachytherapy dosimetry – a phantom study.
The aim of this chapter was to confirm the feasibility of using LiF:Mg,Ti TLDs for in 
vivo prostate brachytherapy dosimetry at St George Hospital.  This was to address the 
lack of dosimeters currently in use for verification of dose delivery in prostate 
brachytherapy.  The investigation was carried out as a phantom study with a view to 
extending toward studies in patients if the TLDs were deemed suitable.  The 
investigation was aimed at determining a consistent correction factor to allow the use 
of an independent control dose to TLDs exposed to radiation from a 6 MV linear 
accelerator for accurately determining the dose delivered to the TLDs using an Ir-192 
source.
4.1 Materials
This section will outline the materials and equipment used for the in vivo dosimetry 
phantom measurements taken as a part of this project.  
4.1.1 Thermoluminescent Dosimeters (TLDs)
Harshaw TLDs (Thermo Electron Corporation, Australia) made of lithium fluoride 
doped with magnesium and titanium (LiF:Mg,Ti) were used in this study.  These 
TLDs are also known as TLD-100 material. They are available in various physical 
forms, however for use inside the brachytherapy needles, cylindrical rods were 
selected.  The dimensions of the TLD rods were 1 mm diameter, 6 mm length, as 
shown in Figure 4.1.  TLDs with a shorter length would provide better spatial 
resolution, however they would be more difficult to manage as the readout carousel 
(as shown in Figure 4.3) is designed for up to 6 mm length rods.  Smaller rods do not 
slot symmetrically into the carousel and can fall through small holes in the bottom of 
the carousel.
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Figure 4.1 LiF:Mg,Ti TLD rods 1mm diameter, 6mm length (Thermo Electron 
Corporation, Australia) stored in an aluminium annealing tray.
4.1.2 TLD Oven
Annealing of the TLDs was performed in a PTW-TLDO oven (PTW Freiburg) as 
shown in Figure 4.2.  The TLDs were stored and annealed in aluminium annealing 
trays, as shown above in Figure 4.1.
Figure 4.2 TLD oven (PTW Freiburg)
6mm
1mm
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4.1.3 TLD Reader
The TLD rods were placed into the rod carousel as shown in Figure 4.3.  They were 
then read in a Harshaw Model 5500 Automatic TLD Reader (Thermo Scientific, 
Australia).  
Figure 4.3 TLD reader and carousel (Thermo Scientific, Australia)
4.1.4 Tweezers
The TLD rods were handled using vacuum tweezers.  The vacuum was produced
using a Dymax 30 pump (Charles Austen Pumps Ltd, Surrey, UK) as shown in Figure 
4.4.  This helped to avoid damaging the sensitive TLD material or allowing body oils 
(from the fingers) to come in contact with the rods.
Figure 4.4 Vacuum tweezers (Charles Austen Pumps Ltd, Surrey UK)
Carousel
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4.1.5 90Sr TLD Irradiator
A strontium-90/yttrium-90 TLD irradiator (Thermo Electron Corporation, Australia –
Model 2210) was used to establish sensitivity factors for the TLDs.  The irradiator is 
shown in Figure 4.5.  As the sensitivity factors are relative readings, the difference in 
energy between 90Sr (average energy ~970 keV) and 192Ir (average energy ~375 keV) 
(Khan, 2003) was expected to have minimal effect on the determination of these 
factors.  The source had a nominal activity of 33 MBq on 4th November 2004 
traceable to international standards (Germany).  The documentation states that the 
dose delivered is 40 µGy per revolution of cobalt-60 equivalent radiation at an 
activity of 33 MBq.
Figure 4.5 TLD irradiator (Thermo Electron Corporation, Australia)
4.1.6 Solid Water Phantom
A custom-made solid water phantom was drilled from a 1 cm thick slab of water-
equivalent material – Goettingen White Water (PTW, Freiburg).  This material is 
specified as water-equivalent in the energy ranges from Cobalt-60 to 25 MV photons, 
however the work described in Section 4.2.5 and the results shown in Figure 4.12 aim 
to verify that the solid water was sufficiently accurate at the lower energies emitted by 
Ir-192 for the purposes of this project.  
A space was drilled for a 6F ProGuide sharp needle (Figure 3.4) in the centre of the 
slab, and holes were drilled surrounding the needle in a grid, each hole large enough 
for the 6 mm TLD rods as described in Section 4.1.1.  The centre of the middle row of 
TLD holes was aligned with the centre of the radioactive source inside the needle as 
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defined by the CT marker.  Figure 4.6 shows this phantom with the space for the 
ProGuide needle.  The holes are spaced 4 mm apart (centre to centre) perpendicular to 
the direction of the needle, and 1 cm (centre to centre) parallel with the axis of the 
needle.
Figure 4.6 Solid water TLD phantom slab with spaces for the ProGuide needle 
and 6 mm length TLD rods
4.1.7 Linear Accelerator
A Varian Clinac iX linear accelerator (Varian Medical Systems, Australia) was used 
for initial testing of the TLDs as well as regular exposures for control measurements 
(Figure 4.7).  6 MV nominal photon energy was used for all linear accelerator 
measurements for this project.
4.1.8 Pulsed Dose Rate Afterloader
A  Pulsed Dose Rate (PDR) remote afterloading device (Nucletron, Australia) 
containing an Ir-192 source (Mallinkrodt B.V. Netherlands) was used for all Ir-192 
measurements in this project (Figure 4.8).  The source was changed approximately 
every 3 months throughout the duration of this project, and each source had an initial 
activity of approximately 2 Ci.  The source design was a version 1 (classic) PDR 
source which consists of two 0.5 mm diameter, 0.5 mm length pellets of solid Iridium 
encapsulated in stainless steel.  A PDR remote afterloading device is essentially the 
same as a high dose rate (HDR) remote afterloading device.  The only difference 
being the activity of the radioactive source.  Typical HDR activities for Ir-192 are 
around 10 Ci.  The PDR unit is currently used at St George Hospital for prostate 
77
brachytherapy in addition to other sites such as oesophagus, bronchus and cervix.  For 
prostate treatments, brachytherapy is delivered using HDR fractionation schemes as 
described in Section 2.1.
Figure 4.7 Varian iX Linear Accelerator (Silhouette Edition) (Varian Medical 
Systems, Australia)
Figure 4.8 PDR Afterloader (Nucletron Pty Ltd, Australia)
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4.2 Methods
Standard deviations were used throughout the analysis procedure to define the errors 
involved.  All standard deviations in this project were calculated using Equation 4.1
(Kirkup 1994): 
)1(
)( 2


n
xx Equation 4.1
Where x is the individual relative response, x is the mean relative response of one 
TLD rod, and n is the sample number.
4.2.1 TLD Oven Readings
The accuracy of the oven temperature was verified to determine if the temperature 
matched the expected temperature.  As outlined in Section 2.3.1.2.4, a lower 
temperature anneal may not clear all electrons from their traps (Kron 1994).  A 
temperature too high may result in a reduced sensitivity of the chips (Horowitz 1990).
This verification was undertaken using a Fluke 52 K/J Thermometer.  Two probes 
were used.  One was placed near the oven’s thermostat and the other in the body of 
the oven (where the TLDs would be placed when annealing).  The position of the 
probes was swapped to rule out any differences in the probes.  Three separate 
readings were taken at 100°C and two at 400°C. The results were plotted and 
compared to the ideal case where the temperature reported by the oven’s thermostat 
matched the independently measured temperature inside the oven.
4.2.2 Initial TLD Preparation
Prior to measurements being taken, three cycles of readouts were undertaken.  The 
TLDs were annealed using the pre-irradiation annealing procedure suggested by the 
manufacturer (1 hour at 400ºC and 2 hours at 100ºC), and exposed to 2 Gy of 6 MV 
photon radiation on the linear accelerator.  This dose was delivered in the solid water 
phantom described in Section 4.1.6 using a 10x10 cm field, TLDs at 100 cm source to 
detector distance, 9 cm solid water backscatter material below the phantom slab, and 
1.5 cm additional solid water buildup.  This setup represents the absolute calibration 
settings for this linear accelerator, translated to a solid phantom setting as opposed to 
the liquid water measurements used for absolute calibration as based on the 
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International Atomic Energy Agency’s protocol detailed in their Technical Report 
Series (TRS) 398 (Andreo, Burns et al, 2000).  200 monitor units (MU) was 
equivalent to 2 Gy delivered to the TLDs on this linear accelerator.  The TLDs were 
then annealed at 100ºC for 10 minutes prior to readout.  
The readout of the TLDs was completed automatically using the TLD Shell software 
supplied with the TLD reader.  The time-temperature profile (TTP) selected heated
the TLD at 15ºC/second to a temperature of 335ºC.  The temperature was then kept 
steady until the readout was complete (total time = 23.3 seconds). 
The TLDs were divided up randomly into 2 sets of 50 rods, named hereafter as Set 1 
and Set 2.
4.2.3 Reproducibility
Set 1 was used to establish reproducibility of this batch of TLDs.  All TLDs were 
annealed, exposed and read under the same conditions as outlined in Section 4.2.2, 
however only 1 Gy (100MU) was delivered.  Reproducibility was determined by 
dividing the raw reading of each rod by the average reading of all 50 rods over a total 
of 12 cycles to give the mean relative response.  The reproducibility of each 
individual rod within the set was evaluated using the standard deviation of the relative 
response.
4.2.4 Sensitivity Factors
Set 2 was used to establish sensitivity factors using the strontium-90 irradiator.  The 
rods were annealed using the same procedure as outlined in Section 4.2.2.  Each TLD 
rod was exposed in the irradiator to 25000 revolutions.  The dose delivered to the 
TLDs was approximately 0.925 Gy, based on the activity of the 90Sr source at the time 
of irradiation and the number of revolutions.  
After this exposure, the post-irradiation anneal of 100ºC for 10 minutes was applied, 
and the rods were read using the same procedure as outlined in Section 4.2.2.  
Sensitivity factors for each rod were calculated by dividing the reading from each 
individual rod by the average reading of all 50 rods in Set 2.  The rods were sorted in 
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order of decreasing sensitivity and the process was repeated three more times.  The 
average of the final three sets of sensitivity factors was used for future measurements.
4.2.5 Iridium-192 Exposures (Initial Testing)
The solid water phantom was used to accurately deliver dose from the PDR unit to 
known distances from the source.  Four 1 cm thick slabs of 30 cm2 solid water 
backscatter material were placed below the phantom slab, and five 1 cm thick slabs of 
solid water placed on top.  Distances approximating the dimensions of a prostate were 
used and Set 2 TLDs were placed at equal distances on both sides of the source and in 
line with the dwell position of the source to obtain an average reading from 2 rods.  
The distances from the source selected for these measurements were: 1.2 cm, 2.0 cm, 
3.2 cm and 4.0 cm.  The TLDs were exposed using the PDR afterloader for 120 
seconds.
The expected dose to the TLDs was calculated using the TG43 formalism in Equation 
4.2 (Nath, Anderson et al. 1995):
),()(),(),(  rFrgrGDeltatSrD k  Equation 4.2
D(r,θ) is the dose at the distance r from the source at angle θ from the source (90º for 
all measurements in this project).  
Sk is the air kerma strength of the source at the time of exposure, measured in units 
cGy cm2 h-1.
t is the exposure time in hours.
Delta, G(r,θ), g(r), F(r,θ) are source-specific parameters taken from Karaiskos, 
Angelopoulos et al. (2003).
The calculated dose was compared with the dose reported by Plato under the same 
conditions using a CT scan of the phantom setup and a single dwell position 
calculation at the date and time of the exposure.
Plato BPS is in full compliance with the TG43 protocol in its dose calculations, 
therefore, this procedure was designed to verify via a spot check that the source data 
had been entered into the planning system correctly for the source and detector 
orientations used in this project.  The TG43 protocol has a high level of accuracy for 
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the sources used in PDR and HDR brachytherapy.  The most uncertainty occurs close 
to the source where there may be significant contribution of dose from electrons from 
the core and source capsule.  Tissue heterogeneities are also not covered by the TG43 
protocol (Meigooni & Wallace, 2005).  These uncertainties were irrelevant to this 
project as all measurements were done in a homogeneous medium (solid water) and at 
distances from the source beyond the level of electron contamination.
Control measurements were taken on the linear accelerator (photon energy = 6 MV) 
using the setup outlined in Section 4.2.2.  Four rods were exposed to each of the 
following doses: 0.2 Gy, 0.5 Gy, 1.0 Gy and 2.0 Gy.  The reading from each of these 
linear accelerator-exposed TLDs was divided by its individual sensitivity factor, and 
the average of the four rods taken to obtain a control reading for each of those doses.
The readings from the Ir-192 exposed TLDs were divided by their individual 
sensitivity factors, and then divided by the control reading closest to their expected 
dose according to the TG43 calculations as per Equation 4.3.  This gave a measured 
dose result, however did not include any correction for the different energy of the Ir-
192 source used for the distance measurements compared with the 6 MV photon beam 
from the linear accelerator used for the control measurements.
ControlSF
R
Dose

 Equation 4.3
Where R = raw TLD reading, SF = Sensitivity Factor, and Control = reading from 
linac exposure divided by the known dose delivered on the linac.
To determine if there was any significant energy change with depth as the radiation 
passed through the solid water, a power fit to the measured data was completed, and 
an inverse square law fit was placed on the data corrected only for individual chip 
sensitivity.  This was normalised to 4 cm depth as the gradient of the depth dose curve 
at this depth is small.  The difference between the curves at the smallest measured 
depth was analysed using the equations of the trend line curves as derived in 
Microsoft Excel.
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4.2.6 Iridium-192 Exposures (Doses similar to those delivered in prostate 
treatments)
On confirmation that the TG43 dose calculation matched the Plato reported dose, and 
therefore confidence that the parameters used in the manual calculation were correct, 
TG43 was again used to calculate the time required to deliver a dose expected in a 
prostate treatment.  
For the in vivo dosimetry measurements, the spare needles where the TLDs may be 
placed are typically within the prostate volume.  Therefore the dose expected would 
be around 100% to 200% of the prescribed dose.  At St George Hospital, the standard 
prescribed dose for a single brachytherapy fraction at the time the patients involved in 
the imaging component of this project were treated was 6.5 Gy, therefore the time to 
deliver 13 Gy (200% of the prescribed dose) to a TLD placed at 1.2 cm from the 
source was calculated using TG43 formalism by rearrangement of Equation 4.2.  The 
doses delivered to TLD positions at 1.6 cm and 2.0 cm, 2.4 cm and 2.8 cm in the time 
calculated above were also calculated by using Equation 4.2.  The same treatment and 
measurement procedure as outlined in Section 4.2.5 was used, however the doses 
delivered to the control TLDs were different to account for the increased dose overall.  
The doses delivered to the control TLDs were 2.4 Gy, 3.3 Gy, 4.7 Gy, 7.3 Gy and 13
Gy to match closely with the doses expected on the TLDs from the Ir-192 exposure 
(based on TG43 calculations).  The first Ir-192 measurement was only undertaken at 
three positions (1.2, 1.6 and 2.0 cm).  All subsequent measurements were undertaken
at all five positions listed above.  A total of nine sets of measurements were taken.
The first two sets of TLDs exposed to these high doses of Ir-192 radiation were re-
read twice following the initial reading to ensure the total charge received on the first 
readout was representing the full dose delivered.  The re-read doses were analysed as 
a percentage of the dose reported in the first readout.
4.2.7 Energy conversion factor (ECF)
The ECF was derived to account for the differences between the radiation spectrum of 
a 6 MV beam from a linear accelerator used for control measurements, and the 
spectrum of the radiation emitted by the Ir-192 source.  It cannot be assumed that the 
response of the TLDs to both spectra will be equivalent.
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The method for determining an ECF was based on the LiF:Mg,Ti TLDs having well 
defined properties when exposed under a 6 MV photon beam from a linear accelerator 
(Kron 1994).  This implies that a known dose delivered to these TLDs using a 6 MV 
linear accelerator will be measured accurately and reliably.  
Calculating the expected dose from an Ir-192 source at a point using the TG43 
formalism has also been shown to give accurate dosimetric results (Nath, Anderson et 
al. 1995; Rivard, Coursey et al. 2004).  
The calculated doses using the TG43 formalism were divided by the measured doses 
from the TLDs exposed to Ir-192 in Section 4.2.6 to obtain the ECF.   This procedure 
was carried out for all nine sets of results and the reproducibility of this factor 
calculated to determine if this was an appropriate method for converting the TLD 
reading to dose.  The results were analysed by plotting the calculated ECFs with 
errors based on standard deviations.  
Investigations were also undertaken to determine if the ECFs were dependent on the 
quantity of dose delivered and the annealing process.  To determine if the ECF was 
dependent on the quantity of dose delivered, the average results for each TLD location 
were plotted.  To determine if the ECF was dependent on the annealing process, the 
last three of the nine sets of results were all annealed at the same time and plotted 
against the average data from all nine sets, giving an assessment of the effect of 
variations in the oven temperature as a potential source of error.
4.2.8 Method to determine Ir-192 doses - theoretical
If these TLDs were deemed accurate and reproducible for in vivo dosimetry using the 
methods described, the combination of the factors derived in Sections 4.2.4 and 4.2.7
could be used to determine the dose read from TLDs exposed to Ir-192 sources.  
Equation 4.4 summarises the method to determine the measured dose:
ControlSF
ECFR
Dose

 Equation 4.4
Where R = raw TLD reading, ECF = Energy Correction Factor, SF = Sensitivity 
Factor, and Control = reading from linac exposure divided by the known dose 
delivered on the linac.
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4.2.9 In vivo measurements - theoretical
In order to use these TLDs for in vivo dose measurements, the rods would be placed 
inside a four French (1.33 mm outer diameter) round ended OncoSmart ProGuide 
needle.  The 1 mm diameter TLD rod slides into this size needle smoothly but would 
need to be held in place with a form of plunger to prevent TLD movement within the 
needle.  The four French needle fits snugly inside the six French needle implanted into 
the patient.  This would allow for dose measurement in the spare needles that would 
be implanted as described in Section 3.2.4.3.  This method is theoretical only and will 
not be attempted as a part of this project.  However it may be applied as a follow-up to 
this project based on the phantom study results presented.
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4.3 Results and Discussion
4.3.1 TLD Oven Readings
The accuracy of the temperature of the annealing oven (Section 4.1.2) was 
investigated.  The results showed that the oven was consistently hotter than the oven’s 
thermostat was reporting.  The temperature in the body of the oven was also 
significantly hotter than the temperature at the thermostat location.  Figure 4.9
displays the results of these measurements in the body of the oven and at a position 
near the thermostat location.  The error bars represent ± one standard deviation from 
the mean result.
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Figure 4.9 TLD annealing oven temperature checks: temperature in the body of 
the oven (green) and temperature near the thermostat (blue).
This shows that the oven thermostat is reading up to almost 85ºC below the actual 
temperature in the body of the oven at the maximum pre-exposure anneal temperature 
(defined as 400ºC).  The oven temperature is not reported accurately by the oven’s 
thermostat.  Reproducibility was found to be within ±15°C at 100°C, and ±5°C at 
400°C.  These results would not be expected to affect the readings from TLDs 
annealed at different times significantly; however this may cause some of the error
noted in the following results, as outlined in Section 2.3.1.2.4.
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4.3.2 Reproducibility
The mean and standard deviation of the relative response for each chip in Set 1 over 
12 readings are shown in Figure 4.10 below.  
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Figure 4.10 Relative reproducibility (Set 1).  Error bars represent one standard 
deviation from the mean of 12 measurements.
The maximum standard deviation for any one rod was 0.014.  It was assumed that Set 
2 has similar characteristics to Set 1 as all of the TLDs came from the same batch.
The error bars in Figure 4.10 represent ± one standard deviation from the mean based 
on 12 readings for each TLD rod.  The TLDs display promising relative 
reproducibility under a 6 MV photon beam from a linear accelerator, comparable to 
results presented by Kirby, Hanson et al. (1992) who found that with a reproducibility 
of 1.5% (1 SD), an overall dose uncertainty of 2% (1 SD) could be achieved.
As this data is for twelve separate measurements, the results show that reproducibility 
is not significantly compromised by the annealing temperature being higher than 
expected, and therefore is not expected to have a significant effect on the 
measurements presented in this thesis.
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4.3.3 Sensitivity Factors
Figure 4.11 below is a plot of the average sensitivity factors of Set 2 and the error bars 
represent ± one standard deviation from the mean.  The downward trend of the data is 
due to the initial sorting of the TLD rods based on their sensitivity factors from the 
first set of measurements.  The results presented here do not include these first results 
but the average of three sets of results taken subsequently.
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Figure 4.11 Average Sensitivity Factors (Set 2). Error bars represent one 
standard deviation from the mean of three measurements.
These results show that the sensitivity factors are reproducible for each TLD rod.  By 
using the average of the three readings in subsequent applications of this correction 
factor, we are further minimising the error caused by the variability in the sensitivity 
of each rod.
This Sr-90 source could be used to expose control TLDs in a similar method to that 
used with the 6 MV exposed TLDs in this project; however exposure of the control 
TLDs to doses expected within the prostate would take several weeks.  Exposing 
control TLDs to lower doses would introduce supralinearity effects, therefore it was 
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deemed more appropriate to investigate control exposure on a 6 MV linear 
accelerator.
4.3.4 Ir-192 Exposures (Initial Tests)
The results of the initial Ir-192 exposures and comparison with TG43 calculations and 
Plato BPS doses are listed in Table 4.1.  The equation used in the TG43 formalism is 
shown in Section 4.2.5 (Equation 4.2).  The doses calculated by Plato BPS match 
closely with those calculated using TG43 as expected. The slight differences are most 
likely due to the inherent error in placing the points accurately in Plato BPS.  This 
verifies that the TG43 calculations have been applied correctly and also that Plato 
BPS can be relied upon to provide accurate dosimetric results based on the latest 
literature available on brachytherapy dosimetry, particularly for simple cases.
Table 4.1 Comparison of TG43 and Plato BPS dose calculations at fixed 
distances from the Ir-192 source.
Figure 4.12 is an average plot of the corrected TLD results (raw reading corrected for 
sensitivity) from the exposures outlined in Section 4.2.5.  The error bars are displayed 
as ±5% which is a typical expected maximum error for LiF:Mg,Ti readings (Kron 
1994).  The blue curve is a fit to the data, showing almost an inverse square 
dependence.  The orange curve is an inverse square trendline normalised to the 
measured data at 4 cm depth where the gradient of the depth dose curve is small and 
positional accuracy will not play a significant role in dose accuracy.  The discrepancy 
between the two curves at the measurement position closest to the Ir-192 source is 0.5 
mm, which is smaller than the diameter of the TLD rod.  This is not entirely 
unexpected as the dose gradient close to the source is very steep and slight errors in 
positioning of the TLDs may result in large differences in the dose.  This plot 
Distance from 
Source (cm)
Calculated Dose 
(TG43) (Gy)
Calculated Dose 
(Plato BPS) (Gy)
Difference (Gy)
1.2 1.5039 1.4919 0.0120
2.0 0.5435 0.5454 0.0019
3.2 0.2140 0.2136 0.0004
4.0 0.1361 0.1365 -0.0004
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indicates that there is no significant effect on measured dose other than the inverse 
square law in the plane perpendicular to the source over distances similar to those 
expected in prostate treatments.  The air gaps in the solid water phantom also do not 
appear to produce any significant differences in dose to the TLDs.  Therefore this 
phantom appears to be viable for relative dosimetry measurements using an Ir-192 
source.
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Figure 4.12 Inverse square fit of TLD data measured in solid water phantom.  
Blue line is a fit to the measured data.  Orange line is an inverse square fit 
normalised to depth 4 cm.  Equations for each trendline are presented on the 
graph.  
4.3.5 Ir-192 Exposures (Doses similar to those delivered in prostate treatments)
The methods for this part of the project are outlined in Section 4.2.6.  A sample 
representation of the detailed results of the measurements is presented in Table 4.2.  
This is a sample only for one set of data.  The other calculations were completed 
identically, with the necessary corrections for source decay based on the time of 
exposure.
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Table 4.2 Calculation of energy conversion factors (ECF) – sample calculation
Figure 4.13 is a plot of the average conversion factors for the individual measurement 
dates.  The error bars represent ± one standard deviation from the mean.  The results 
range from 0.863 to 0.917 with an average of 0.891 (with one standard deviation of 
0.02).  This represents acceptable reproducibility of the conversion factor.
There appears to be minimal dependence of the conversion factor on the dose as 
shown in Table 4.3 and Figure 4.14.  Table 4.3 is a summary of the results and shows 
the average conversion factor from all nine measurements separated into their dose 
groups (or distance from the source).  
Linear Accelerator Control Measurements
Dose (cGy)
Average Corrected 
Reading (nC)
Reading/cGy
1300 27483.03 21.14
730 14010.76 19.19
470 8687.96 18.49
Ir-192 Measurements
Distance from 
Source (cm)
TG43 Calculated 
Dose (cGy)
Measured Dose 
(corrected TLD reading 
÷ control 
“Reading/cGy”) (cGy)
Energy conversion 
factor (ECF)
1.2 1300.86
1422.7327 0.914
1403.5154 0.927
1.6 732.90
814.5703 0.900
788.2756 0.930
2.0 469.80
517.9096 0.907
509.5391 0.922
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Figure 4.13 Average energy conversion factors for each separate Ir-192 exposure
Figure 4.14 is a plot of the average conversion factors for each distance from the 
source.  The standard deviation of the nine results is small, indicating that the 
reproducibility of results using the TLDs for Ir-192 dose measurements under these 
conditions is suitable for in vivo dosimetry.  The error bars on this plot represent ± one 
standard deviation from the mean.  At the position closest to the Ir-192 source, the 
factor was calculated to be higher than at other positions.  This is likely to be due to 
the steep dose gradient at this proximity to the source, resulting in a difference 
between the measured and calculated doses.
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Figure 4.14 Average conversion factors for using 6MV linear accelerator control 
TLDs with Ir-192 measurement TLDs
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Table 4.3 Conversion factors for using 6MV linear accelerator control TLDs with Ir-192 measurement TLDs
Distance 
from Source 
(cm)
Control 
Dose 
(cGy)
Measured Conversion Factors Average 
Conversion 
Factor
SD
21-Jan 11-Feb 11-Feb 3-Mar 3-Mar 10-Mar 31-Mar 31-Mar 31-Mar
1.2 1300
0.914 0.951 0.969 0.886 0.908 0.929 0.876 0.871 0.882
0.921 0.03
0.927 0.961 0.969 0.911 0.895 0.917 0.936 0.936 0.939
1.6 730
0.900 0.929 0.919 0.865 0.871 0.878 0.886 0.864 0.882
0.889 0.03
0.930 0.905 0.905 0.862 0.831 0.861 0.903 0.891 0.918
2.0 470
0.907 0.908 0.911 0.857 0.858 0.888 0.849 0.836 0.901
0.882 0.03
0.922 0.896 0.903 0.854 0.857 0.868 0.875 0.873 0.908
2.4 330
- 0.908 0.916 0.876 0.883 0.884 0.878 0.894 0.868
0.883 0.02
- 0.902 0.895 0.850 0.869 0.850 0.872 0.886 0.898
2.8 240
- 0.902 0.865 0.851 0.832 0.861 0.872 0.874 0.925
0.876 0.03
- 0.908 0.867 0.854 0.826 0.855 0.915 0.884 0.923
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The first re-read of the Ir-192 exposed TLDs gave an average of 0.18% of the dose in 
the first readout.  The second re-read gave an average of 0.07%.  This showed that 
almost all of the electrons trapped in the impurities of the crystal were released from 
the traps and included in the first readout.  The extra dose obtained from the re-read is 
insignificant compared to the expected errors from these measurements.  It is 
therefore not necessary to repeat the readout.
As a further investigation, the last three of the nine results were all completed with the 
entire tray of TLDs placed into the annealing oven at the same time.  The TLDs 
therefore received exactly the same pre-exposure and pre-read anneal temperatures, 
and the three Ir-192 exposures were analysed using the same set of linear accelerator
exposed control TLDs.  The results are displayed below in Figure 4.15.
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Figure 4.15 Conversion factors for entire TLD set annealed together (3 readings 
– yellow series) and overall results for all nine readings (blue series).
The results for the single anneal process for all three exposures follows the same 
pattern on average as the overall data.  There is no significant benefit in annealing the 
control and measurement TLDs at the same time as slight variations in the oven’s 
temperature control do not appear to have a significant effect on the results.  
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From these results, the average ECF was calculated to be 0.891.  This average was 
calculated including the measurement point closest to the Ir-192 source, as clinical 
measurement situations may result in the TLD being placed this close to a source 
position.  This factor could be applied to the raw doses measured from the Ir-192 
exposures to give in vivo dosimetry results.  This corresponds to an over-response of 
the TLDs at Ir-192 energies of approximately 11% - a significantly greater difference 
than that reported by Williamson and Rivard (2005) of approximately 4%.  The 
additional error introduced into the in vivo measurement by using this factor is ±2% 
(for one standard deviation).  As current techniques for external beam TLD 
measurements can give results in the therapeutic range with accuracies up to ±2% 
(Kron 1994), the expected error in HDR TLD measurements would be in the order of 
±4%.  
Further investigations to pursue the use of LiF:Mg,Ti TLDs for HDR and PDR 
prostate brachytherapy in vivo dosimetry could involve the use of the Ir-192 source as 
the control measurements.  The main disadvantage of this method is that it uses the 
same source for calibration as is used for the in vivo dose measurements.  Although 
this method of using the same radiation source for control measurement and dose 
delivery is used for external beam in vivo dose measurements, the LiF:Mg,Ti TLDs 
are well established in this area, whereas their properties are less certain at Ir-192 
energies.  This method could be useful for detection of deviation in dose delivered 
compared with planned dose, however it does not provide an independent check that 
the source calibration is correctly entered into the planning system.
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Chapter 5: Conclusions
The aim of this thesis was to investigate potential improvements on two areas in HDR 
and PDR prostate brachytherapy - the definition of the prostate and treatment delivery 
verification.
The results of the study into the use of MRI for improving the definition of the 
prostate showed similar trends to the literature in that the CT volume was larger than 
the MR volume of the prostate.  The results did not give conclusive evidence that the 
use of MR imaging improved the consistency between Oncologists in defining the 
prostate.  
Since the MR images define the prostate to be smaller than that defined with CT 
images, MRI may have a place in prostate brachytherapy to reduce the dose to normal 
tissue surrounding the prostate.  This statement assumes that the prostate volume 
delineated using the MR images is more accurate than that generated using CT 
images.  The use of MR could therefore result in more conformal coverage of the 
target volume without compromising the surrounding critical structures.
Extension of the study to a much larger study incorporating more patients and in 
particular more Oncologists to delineate the structures on the different modalities 
would give a more statistically rigorous set of results.  At the time of publication of 
this thesis, plans for this extended study have begun at St George and Liverpool 
Hospitals.
LiF:Mg,Ti TLDs have been shown in this thesis to have acceptable accuracy when 
measuring radiation dose from an Ir-192 source.  An energy conversion factor to 
allow the use of control TLDs exposed to 6 MV radiation from a linear accelerator has 
been derived empirically and shown to be effective.  This could in principle be 
applied to in vivo dose measurements to verify the dose delivered to the patient.  
Phantom results indicate the accuracy of such measurements is achievable to within 
±4% using existing systems at St George Hospital.
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Further investigation is required to verify if this technique gives accurate results under 
the less structured setup inherent with in vivo measurements.  It is also recommended 
that the conversion factor be verified for individual centres based on the linear 
accelerator calibration beam that the control TLDs are exposed to.
The recommended in vivo trial is under consideration for 2009 following local ethics 
committee approval at St George Hospital.
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Appendix A: Glossary
All terms in the glossary, unless otherwise stated, were defined with the assistance of 
Wikipedia (http://www.wikipedia.org).
Anisotropy – describes the directional dependence of the source.  Simple dose 
models assume point-source geometry, however the design of the source is such that it 
does not emit a spherical radiation distribution, but is influenced by the length of the 
source and the positioning of the cable to which the source is attached.  The 
anisotropy function describes the variation in dose as a function of the polar angle 
relative to the transverse plane of the source (Rivard, Coursey et al. 2004)
Brachytherapy – a form of radiotherapy where a radioactive source is placed inside 
or next to the area requiring treatment.  From the Greek brachy meaning “short”.
Intensity-modulated radiation therapy (IMRT) – an advanced type of radiotherapy 
using dynamic multi-leaf collimators on a linear accelerator to optimise the dose 
delivery to the target tissue, minimising dose to the surrounding normal tissue and 
critical structures.
High Dose Rate (HDR) – defined in brachytherapy as a dose rate of 12 Gy per hour
or greater (Nath 2005).  
Linear Accelerator – an electrical device for the acceleration of subatomic particles.  
Used in a hospital environment to accelerate electrons to produce high energy photon 
or electron beams for external beam radiotherapy.
Lithotomy – a common position for surgical procedures involving the pelvis and 
lower abdomen.  The patient is lain on the back with knees bent, positioned above the 
hips and spread apart through the use of stirrups.
Low Dose Rate (LDR) – defined in brachytherapy as a dose rate from 0.4 to 2 Gy per 
hour (Nath 2005).
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Patient Points – points placed on the treatment plan.  The planning system reports the 
dose delivered to each of these points.  They can also be used as prescription points or 
dose optimisation points within the Plato Brachytherapy planning system.
Peripheral Zone – the region of the prostate to which the dose coverage should be 
optimal.  It is typically a horseshoe shape following the outline of the prostate, but 
cutting in around the urethra.  This is a slightly modified definition compared to the 
standard definition of peripheral zone, which is the sub-capsular portion of the 
posterior aspect of the prostate gland surrounding the distal urethra.  It is from this 
region that 70% of prostatic cancers originate.
Proctitis – a potential side-effect of prostate brachytherapy if the dose to the rectum is 
excessive.  It is an inflammation of the anus and lining of the rectum, causing 
diarrhoea and rectal bleeding amongst other symptoms.
Pulsed Dose Rate (PDR) – usually a medium dose rate source (medium dose rate is 
defined as 2 to 12 Gy per hour) (Nath 2005), used in a pulsed manner (for example 
one short pulse every hour) to achieve a similar treatment outcome to LDR
brachytherapy.
Toxicity – the damage caused by ionising radiation to tissue.
Radial Dose Function – a parameter used to account for dose fall-off on the 
transverse plane of the source due to photon scattering and attenuation. It can also be 
influenced by filtration of photons by the encapsulation of the source and the source 
materials themselves (Nath, Anderson et al. 1995).
Remote afterloading device – a treatment machine containing a radioactive source 
that is inserted and retracted from the applicators in the patient by a computer-
controlled mechanism.  Remote afterloaders prevent high doses to staff as they are 
operated from outside of the treatment room, behind shielding.
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TE Echo time – the time in milliseconds between the application of the 90º pulse and 
the peak of the echo signal in Spin Echo and Inversion Recovery pulses in MRI
(FONAR 2003).
TR Repetition time – a parameter used in MRI to define the amount of time between 
successive pulse sequences applied to the same slice.  Variations in this parameter 
control the image contrast characteristics (FONAR 2003).
Urethral stricture – a potential side effect of prostate brachytherapy if the dose to the 
urethra is excessive.  It is a narrowing of the urethra causing side effects such as 
decreased force of urinary stream, incomplete bladder emptying, urinary terminal 
dribbling, increased frequency and acute or chronic retention of urine.
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